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1. INTRODUCTION 
Chemistry is the study of matter, including its composition, structure, 
physical properties, and reactivity. There are many approaches to studying 
chemistry, but for convenience, we traditionally divide it into five fields: organic, 
inorganic, physical, biochemical, and analytical. Although this division is historical 
and arbitrary, as witnessed by the current interest in interdisciplinary areas such as 
bio analytical and organometallic chemistry, these five fields remain the simplest 
division spanning the discipline of chemistry. Analytical chemistry is often 
described as the area of chemistry responsible for characterizing the composition of 
matter, both qualitatively (what is present) and quantitatively (how much is 
present)1. 
Analytical chemistry may be defined as the “Science and art of determining 
the composition of materials in terms of the elements or compounds contained”. 
Pharmaceutical analysis plays a major role today, and it can be considered as an 
interdisciplinary subject. Pharmaceutical analysis derives its principles from various 
branches of science like Chemistry, Physics, Microbiology, Nuclear Science, 
Electronics, etc. 
Analytical method is a specific application of a technique to solve an 
analytical problem. Analytical instrumentation plays an important role in the 
production and evaluation of new products and in the protection of consumers and 
the environment. This instrumentation provides the lower detection limits required 
to assure safe foods, drugs, water and air, generally used for drug analysis are 
spectral methods, chromatographic methods, electro analytical techniques, and 
miscellaneous techniques like conventional titrimetric, gravimetric and Polari metric 
methods.  
Pharmaceutical analysis techniques are applied mainly in two areas 
traditionally: 
Analytical chemistry has been split into two main types. They are qualitative 
and quantitative: 
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 Qualitative 
Qualitative analysis seeks to establish the presence of a given element or  
compound in a sample. 
 Quantitative  
Quantitative analysis seeks to establish the amount of a given element or 
compound in a sample. 
Specific Technologies and Instrumentation  
A) Spectrometric Techniques: 
1. Ultraviolet and visible Spectrophotometer 
2. Fluorescence and phosphorescence Spectrophotometer 
3. Atomic Spectrometry (Emission and Absorption) 
4. Infrared Spectrophotometer   
5. Raman Spectroscopy 
6. X-Ray Spectroscopy 
7. Radiochemical Techniques including activation analysis  
8. Nuclear Magnetic Resonance Spectroscopy 
9. Electron Spin Resonance Spectroscopy 
B) Electrochemical Techniques:  
      1. Potentiometer 
      2. Voltametry 
      3. Volta metric Techniques 
      4. Amperometric Techniques 
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      5. Colorimetry 
      6. Electrogravimetry 
      7. Conductance Techniques 
C) Chromatographic Techniques: 
1. Gas Chromatography 
2. High performance Liquid Chromatography 
3. Thin Layer Chromatography 
4. Ultra performance Liquid Chromatography 
D) Miscellaneous Techniques: 
1. Thermal Analysis 
2. Mass Spectrometry 
3. Kinetic Techniques 
1.1 ANALYTICAL METHOD DEVELOPMENT: 
The number of drugs introduced into the market is increasing every year. 
These Drugs may be either new entities or partial structural modification of the 
existing one. Very often there is a time lag from the date of introduction of a drug 
into the market to the date of its inclusion in pharmacopeias. This happens due to the 
possible uncertainties in the continuous and wider usage of these drugs, reports of 
new toxicities (Resulting in their withdrawal from the market), development of 
Patient resistance and introduction of better drugs by competitors. Under these 
conditions, standards and analytical procedures for these drugs may not be available 
in the Pharmacopeia. Therefore it becomes necessary to develop newer analytical 
methods for such drugs2. 
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Basic Criteria for New Method Development Of Drug Analysis:  
 The drug or drug combination may not be official in any pharmacopoeias.   
 A proper analytical procedure for the drug may not be available in the literature 
due to patent regulations; Analytical methods may not be available for the drug 
in the form of a formulation due to the interference caused by the formulation 
excipient. 
 Analytical methods for the quantitation of the drug in biological fluids may not 
be available. Analytical methods for a drug in combination with other drugs may 
not be available and the existing analytical procedures may require expensive 
reagents and solvents.  
 It may also involve cumbersome extraction and separation procedures and these 
may not be reliable. 
Steps Involved In Method Development: 
Documentation starts at the very beginning of the development process. A 
system for full documentation of development studies must be established. All data 
relating to these studies must be recorded in laboratory notebook or an electronic 
database3.  
1. Analyte standard characterization: 
a) All known information about the analyte and its structure is collected i.e., 
physical and chemical properties. 
b) The standard analyte (100 % purity) is obtained.  Necessary arrangement is 
made for the proper storage (refrigerator, desiccators and freezer). 
c) When multiple components are to be analyzed in the sample matrix, the number 
of components is noted, data is assembled and the availability of standards for 
each one is determined. 
Only those methods (Spectroscopic, MS, GC, HPLC etc.,) that are compatible with 
sample stability are considered.  
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2. Method requirements: 
The goals or requirements of the analytical method that need to be developed 
are considered and the analytical figures of merit are defined.  The required 
detection limits, selectivity, linearity, range, accuracy and precision are defined.  
3. Literature search and prior methodology: 
 The literature for all types of information related to the analyte is surveyed. 
For synthesis, physical and chemical properties, solubility and relevant analytical 
methods, books, periodicals, chemical manufacturers and regulatory agency 
compendia such as USP / NF are reviewed. Chemical Abstracts Service (CAS) 
automated computerized literature searches are convenient.  
4. Choosing a method: 
a) Using the information in the literatures and prints, methodology is adapted.  
The methods are modified wherever necessary. Sometimes it is necessary to 
acquire additional instrumentation to reproduce, modify, improve or validate 
existing methods for in-house analytes and samples. 
b) If there are no prior methods for the analyte in the literature, from analogy, the 
compounds that are similar in structure and chemical properties are investigated 
and are worked out.  
c) There is usually one compound for which analytical method already exist that is 
similar to the analyte of interest. 
5. Instrumental setup and initial studies: 
   The required instrumentation is setup. Installation, operational and 
performance qualification of instrumentation using laboratory standard operating 
procedures (SOP’s) are verified. Always new consumables (e.g. solvents, filters and 
gases) are used. For example, method development is never started on a HPLC 
column that has been used earlier. The analyte standard in a suitable injection / 
introduction solution and in known concentrations and solvents are prepared. It is 
important to start with an authentic, known standard rather than with a complex 
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sample matrix. If the sample is extremely close to the standard (e.g., bulk drug), then 
it is possible to start work with the actual sample4. 
6. Optimization: 
   During optimization, one parameter is changed at a time and set of 
conditions are isolated, rather than using a trial and error approach. Work has been 
done from an organized methodical plan, and every step is documented (in a lab 
notebook) in case of dead ends. 
7. Documentation of analytical figures of merit: 
   The originally determined analytical figures of merit are Limit of 
Quantification (LOQ), Limit of Detection (LOD), linearity, time per analysis, cost, 
sample preparation etc., are documented. 
8. Evaluation of method development with actual samples: 
   The sample solution should lead to unequivocal, absolute identification of 
the analyte peak of interest apart from all other matrix components.  
9. Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis: 
   Percent recovery of spiked, authentic standard analyte into a sample matrix 
that is shown to contain no analyte is determined.  Reproducibility of recovery 
(average + / - standard deviation) from sample to sample and whether recovery has 
been optimized or not has been shown. It is not necessary to obtain 100 % recovery 
as long as the results are reproducible and known with a high degree of certainty. 
The validity of analytical method can be verified only by laboratory studies.  
Therefore Documentation of the successful completion of such studies is a basic 
requirement for Determining whether a method is suitable for its intended 
applications5. 
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1.2 CHROMATOGRAPHY  
 Chromatography (Chroma means ‘color’ and graphein means to ‘write’) is 
the collective term for a set of laboratory techniques for the separation of mixtures. 
It involves passing a mixture dissolved in a "mobile phase" through a stationary 
phase, which separates the analyte to be measured from other molecules in the 
mixture based on differential partitioning between the mobile and stationary phases. 
Differences in compounds partition coefficient results in differential retention on the 
stationary phase and thus changing the separation. Chromatography is defined as a 
chemical analysis separation process which uses selective adsorption to segregate 
and identify components of complex mixtures such as solutions, liquids and vapors. 
Different types of Chromatographic techniques were summarized in table.1.3 
 Chromatography may be preparative or analytical. The purpose of 
preparative Chromatography is to separate the components of a mixture for further 
use (and is thus a form of purification). Analytical Chromatography is done 
normally with smaller amounts of material and is for measuring the relative 
proportion of analytes in a mixture6. 
Table 1.3 Different Types of Chromatographic Techniques 
Basic principle involved Type of Chromatography 
Techniques by Chromatographic bed 
shape 
Column Chromatography 
Paper Chromatography 
Thin layer Chromatography 
Techniques by physical state of mobile 
phase 
Gas Chromatography 
Liquid Chromatography 
Affinity Chromatography Supercritical fluid Chromatography 
Techniques by separation mechanism Ion Exchange Chromatography 
Size Exclusion Chromatography 
Special techniques Reversed Phase Chromatography 
Two-dimensional Chromatography 
Simulated Moving-Bed Chromatography 
Pyrolysis Gas Chromatography 
Fast Protein Liquid Chromatography 
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High Performance Liquid Chromatography (HPLC): 
In the modern pharmaceutical industry, High Performance Liquid 
Chromatography (HPLC) is the major and integral analytical tool applied in all 
stages of drug discovery, development, and production. Effective and fast method 
development is of paramount importance throughout this drug development life 
cycle. This requires a thorough understanding of HPLC principles and theory which 
lay a solid foundation for appreciating the many variables that are optimized during 
fast and effective HPLC method development and optimization. Chromatographic 
separations are based on a forced transport of the liquid (mobile phase) carrying the 
analyte mixture through the porous media and the differences in the interactions at 
analytes with the surface of this porous media resulting in different migration times 
for a mixture components.  
High surface area of the interface between mobile and stationary phases is 
essential for space discrimination of different components in the mixture. Analyte 
molecules undergo multiple phase transitions between mobile phase and adsorbent 
surface. 
Average residence time of the molecule on the stationary phase surface is 
dependent on the interaction energy. For different molecules with very small 
interaction energy difference the presence of significant surface is critical since the 
higher the number of phase transitions that analyte molecules undergo while moving 
through the chromatographic column, the higher the difference in their retention7. 
The nature of the stationary and the mobile phases, together with the mode of 
the transport through the column, is the basis for the classification of 
Chromatographic methods10. 
The four main types of HPLC techniques are  
1. Normal-Phase Chromatography. 
2. Reversed-Phase Chromatography. 
3. Ion-Exchange Chromatography. 
4. Size-Exclusion Chromatography. 
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Normal-Phase Chromatography: 
The term "normal phase" is used to denote a chromatographic system in 
which a polar stationary phase is employed and a less polar mobile phase is used for 
elution of the analytes. In the normal-phase mode, neutral solutes in solution are 
separated on the basis of their polarity; the more polar the solute, the greater is its 
retention on the column. Since the mobile phase is less polar than the stationary 
phase, increasing the polarity of the mobile phase results in decreased solute 
retention. Normal-Phase chromatography is most commonly applied to the analysis 
of samples that are soluble in non-polar solvents, and it is particularly well suited to 
the separation of isomers and to class separations. 
Although the separation mode has occasionally been misidentified as 
reversed phase, it is normal phase by virtue of the fact that increased aqueous levels 
of the mobile phase reduce carbohydrate retention, and elution order follows 
carbohydrate polarity. Normal-phase separations have occasionally been combined 
off-line with Reversed-phase chromatography to separate a wider range of species 
than could be accomplished by either technique alone. The feasibility of such a 
system, however, is contingent on the compatibility of the normal-phase eluent with 
that of the reversed-phase column8. 
Reversed-Phase Chromatography: 
As the name suggests, Reversed-Phase Chromatography is the reverse of 
Normal-Phase Chromatography in the sense that it involves the use of a non-polar 
stationary phase and a polar mobile phase. As a result, a decrease in the polarity of 
the mobile phase results in a decrease in solute retention. Modern Reversed-Phase 
Chromatography typically refers to the use of chemically bonded stationary phases, 
where a functional group is bonded to silica, for this reason, Reversed-Phase 
Chromatography is often referred to in the literature as Bonded-Phase 
Chromatography. Occasionally, however, polymeric stationary phases such as 
polymathacrylate or polystyrene, or solid stationary phases such as porous graphitic 
carbon, are used. Weak acids and weak bases, for which ionization can be 
suppressed, may be separated on reversed-phase columns by the technique known as 
ion suppression. In this technique a buffer of appropriate pH is added to the mobile 
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phase to render the analyte neutral or only partially charged. Acidic buffers such as 
acetic acid are used for the separation of weak acids, and alkaline buffers are used 
for the separation of weak bases. The analysis of strong acids or strong bases using 
reversed-phase columns is typically accomplished by the technique known as ion-
pair chromatography (also commonly called paired-ion or ion-interaction 
chromatography). In this technique, the pH of the eluent is adjusted in order to 
encourage ionization of the sample; for acids pH 7.5 is used, and for bases pH 3.5 is 
common. Reversed-Phase Chromatography is the most popular mode for the 
separation of low molecular weight (<3000), neutral species that are soluble in water 
or other polar solvents. It is widely used in the pharmaceutical industry for 
separation of species such as steroids, vitamins, and β-blockers. Because of the 
mobile phase in Reversed-Phase Chromatography is polar, Reversed-Phase 
Chromatography is suited to the separation of polar molecules that either are 
insoluble in organic solvents or bind too strongly to the polar, normal-phase 
materials9. 
Ion-Exchange Chromatography: 
In Ion-Exchange Chromatography (IEC), species are separated on the basis 
of differences in electric charge. The primary mechanism of retention is the 
electrostatic attraction of ionic solutes in solution to "fixed ions" of opposite charge 
on the stationary phase support. The stationary phase or ion exchanger is classified 
as an anion-exchange material when the fixed ion carries a positive charge and as a 
cation exchanger when it carries a negative charge. 
A specialized form of IEC is ion chromatography (IC), which is the name 
applied to the analysis of inorganic anions, cations, and low molecular weight, 
water-soluble organic acids and bases. Although any HPLC technique used to 
separate the above species can be termed ion chromatography, in general IC 
involves the use of ion-exchange columns and a conductivity detector. Ion 
chromatography itself can be sub classified. Suppressed IC involves the use of a 
membrane device, known as a suppressor, between the column and the detector to 
lower the response of the eluent and thereby enhance the signal from the solute; 
nonsuppressed or "single-column" IC does not contain a suppressor. 
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Size-Exclusion Chromatography: 
Size-Exclusion Chromatography (SEC) is a convenient and highly 
predictable method for separating simple mixtures whose components are 
sufficiently different in molecular weight. For small molecules, a size difference of 
more than about 10% is required for acceptable resolution; for macromolecules a 
twofold difference in molecular weight is necessary15. Size-Exclusion 
Chromatography can be used to indicate the complexity of a sample mixture and to 
provide approximate molecular weight values for the components. It is an easy 
technique to understand, and SEC can be applied to the separation of delicate bio 
macromolecules as well as to the separation of synthetic organic polymers. Because 
SEC is a gentle technique, rarely resulting in loss of sample or reaction, it has 
become a popular choice for the separation of biologically active molecules. Each 
solute is retained as a relatively narrow band, which facilitates solute detection with 
detectors of only moderate sensitivity. One of the major applications of SEC is 
polymer characterization10. 
1.4 INSTRUMENTATION: 
 The basic components of a High Performance Liquid Chromatographic 
system are shown in Fig.1. The instrument consists of 
 1. Mobile Phase Reservoir 
 2. A pump to move the eluent and sample through the system. 
 3. An injection device to allow sample introduction. 
 4. A Column(s) to provide solute separation. 
 5. A Detector to visualize the separated components. 
 6. A Data collection device to assist in interpretation and storage of results. 
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1. Mobile Phase Reservoir: 
The most common type of solvent reservoir is a glass bottle. Most of the 
manufacturer’s supply these bottles with special caps, Teflon tubing and filters to 
connect to the pump inlet t and to the spurge gas (Helium) used to Remove 
Dissolved air. Filtration is needed to eliminate suspended Particles and organic 
impurities. 
Solvent
Pump
AutoSampler
Injector
Column
Detector
Waste
Data System
 
Fig. 1.5 Basic Components of HPLC System 
Solvent System: 
The mobile phases used in Reversed-Phase Chromatography are based on a 
polar solvent, typically water, to which a less polar solvent such as acetonitrile or 
methanol is added. Solvent selectivity is controlled by the nature of the added 
solvent in the same way as was described for Normal-Phase Chromatography. 
Solvents with large dipole moments, such as methylene chloride and 1, 2-
dichloroethane interacts preferentially with solutes that have large dipole moments 
such as nitro-compounds, nitriles, amines, and sulfoxides. Solvents that are good 
proton donors such as chloroform, m-cresol, and water interact preferentially with 
basic solutes such as amines and sulfoxides and solvents that are good proton 
acceptors such as alcohols, ethers, and amines, tend to interact best with 
hydroxylated molecules such as acids and phenols. List of some useful solvents for 
use as mobile phases in Reversed-Phase Chromatography are listed below11. 
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Table No 1.6 Mobile Phases in RP-HPLC 
Solvent Polarity/elution strength 
Water 10.2 
Dimethyl sulfoxide 7.2 
Ethylene glycol 6.9 
Acetonitrile 5.8 
Methanol 5.1 
Acetone 5.1 
Dioxane 4.8 
Ethanol 4.3 
Tetrahydrofuran 4.0 
2-Propanol 3.9 
 
Solvent Degassing System: 
The constituents of the mobile phase should be degassed and filtered before 
use. Several methods are employed to remove the dissolved gases in the mobile 
phase. They include heating and stirring, vacuum degassing with an aspirator, 
filtration through 0.45 filters, vacuum degassing with an air-soluble membrane, 
helium purging ultra sonification or purging or combination of these methods. 
HPLC systems are also provided an online degassing system, which continuously 
removes the dissolved gases from the mobile phase12. 
Gradient Elution Devices: 
HPLC columns may be run isocratically, i.e., with constant eluent or they 
may be run in the gradient elution mode in which the mobile phase composition 
varies during run. Gradient elution over comes the problem of dealing with a 
complex mixture of solutes.  
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Stationary Phases: 
In Liquid–Liquid Chromatography the stationary phase is a liquid film 
coated on a packing material consisting of 3–10 mm porous silica particles. The 
stationary phase may be partially soluble in the mobile phase, causing it to “bleed” 
from the column over time. To prevent this loss of stationary phase it is covalently 
bound to the silica particles. Bonded stationary phases are attached by reacting the 
silica particles with an organochlorosilane of the general form Si (CH3)2RCl, where 
R is an alkyl or substituted alkyl group. To prevent unwanted interactions between 
the solutes and any unreacted –SiOH groups the silica frequently is “capped” by 
reacting it with Si (CH3)3Cl; such columns are designated as end-capped. The 
properties of a stationary phase are determined by the nature of the organosilane’s 
alkyl group. If R is a polar functional group then the stationary phase will be polar. 
Since the stationary phase is polar, the mobile phase is a nonpolar or moderately 
polar solvent. The combination of a polar stationary phase and a nonpolar mobile 
phase is called normal phase chromatography.  
In reverse phase chromatography, which is the more commonly encountered 
form of HPLC, the stationary phase is nonpolar and the mobile phase is polar. The 
most common nonpolar stationary phases use an organochlorosilane for which the R 
group is an n-octyl (C8) or n-octadecyl (C18) hydrocarbon chain. Most reverse phase 
separations are carried out using a buffered aqueous solution as a polar mobile 
phase13. 
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Table 1.7 BONDED STATIONARY PHASES FOR HPLC 
STATIONARY 
PHASE 
FUNCTIONAL 
GROUP 
APPLICATIONS 
Silica Si-OH 
Normal phase material Pesticides,  
alkaloids  
C18 Octadecyl 
Reverse-phase material 
Fatty acids, PAH, Vitamins 
C8 Octyl 
Reverse-phase and ion pair, Peptides 
proteins 
C6H5 Phenyl 
Reverse-phase 
Polar aromatic fatty acids. 
CN Cyano 
Normal and Reverse-phase, polar 
compounds 
NO2 Nitro 
Normal and Reverse-phase, PAH, 
Aromatic compounds 
NH2 Amino 
Normal, Reverse,  
weak ion exchange Carbohydrates, 
organic acids, chlorinated pesticides 
OH Diol 
Normal, Reverse phase peptides, 
proteins. 
SA Sulphonic acid 
Cation exchange, separation of 
cations. 
 
2. PUMPS: 
Pumps are used to   flow   mobile phase at high pressure and at controlled 
flow rates. The pumps must be capable of generating pressure of up to 5000 psi at 
flow rates up to 3ml/min for analytical purpose. Pumps used in   preparative scale 
hplc may be required to pump at flow rates of upto20ml/min. 
Classification of pumps: 
HPLC pump can be classified in to the following groups according to the manner in 
which they operate:  
 Constant flow rate pump (or) constant displacement pump 
                    i) Reciprocating piston pump 
                    ii) Syringe drive pump 
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 Constant pressure pump 
                     i) Simple gas displacement pump 
                     ii) Pneumatic amplifier pump  
a) Reciprocating pump 
 Reciprocating pumps usually consist of a small chamber in which the solvent 
is pumped by the back and forth motion of a motor driven piston.  Two check valves 
control the flow of solvent.  Reciprocating pumps have a disadvantage of producing 
pulsed flow, which must be damped as its presence is manifested as base line noise 
on the chromatogram.  Advantages of this pump include their small internal volume, 
high output pressure, ready adaptability to gradient elution, and independent of 
column backpressure and viscosity of solvent14. 
b)  Displacement pump 
 Displacement pumps usually consist of large syringe like chambers equipped 
with a plunger that is activated by a screw driven mechanism powered by stepping 
motor.  Displacement pumps also produce a flow that tends to be independent of 
viscosity and backpressure.  In addition, the output is pulse free. Disadvantages 
include limited solvent capacity (250 ml) and considerable inconvenience when 
solvents must be changed15. 
c) Pneumatic pumps 
 In pneumatic pumps, the mobile phase is contained in a collapsible container 
housed in a vessel that can be pressurized by a compressor gas.  Pumps of this kind 
are inexpensive and pulse free.  They suffer from limited capacity, pressure output, 
dependence of flow rate on solvent viscosity and column backpressure.  In addition, 
they are not amenable to gradient elution and are limited to pressures less than about 
2000 psi16. 
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3. SAMPLE INJECTION SYSTEM: 
Sample introduction can be accomplished in various ways. The simplest 
method is to use an injection valve. In more sophisticated LC systems, automatic 
sampling devices are incorporated where the sample is introduced with the help of 
auto samplers and microprocessors. In liquid chromatography, liquid samples may 
be injected directly and solid samples need only be dissolved in an appropriate 
solvent. The solvent need not be the mobile phase, but frequently it is judiciously 
chosen to avoid detector interference, column/component interference, loss 
inefficiency or all of these. It is always best to remove particles from the sample by 
filtering over a 5 μm filter, or centrifuging, since continuous injections of particulate 
material will eventually cause blockages in injection devices or columns. Sample 
sizes may vary widely17.  
The availability of highly sensitive detectors frequently allows use of the 
small samples which yield the highest column performance. 
Examples of injectors are shown in Fig 2 and Fig 3. 
  
 Fig 2.2: Load Sample Fig 2.3Inject Sample 
4. COLUMNS: 
  The column is the heart of the chromatograph, providing the means for 
separating a mixture into components. The selectivity, capacity, and efficiency of 
the column are all affected by the nature of the packing material or the materials of 
construction18.  
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Requirements for an Ideal HPLC Column: 
1. Particles should be spherical and available in particle diameters ranging from 3 
to10 µm. 
2. Particles should withstand typical pressures encountered during HPLC ((900-
3000 psi (6.1- 20.5 MPa) but ideally up to 4000 psi (27.2 MPa)) and should not 
swell or shrink with the nature of the eluent. 
3. Particles should have porosity in the range 50-70%, extending to 80 % for Size-
Exclusion Chromatography. 
4. Particles should contain no pores smaller than ~60 A0 in diameter and should 
have a uniform pore size distribution. 
5. Particles should be available with a range of mean pore diameters of 60-1000 A0. 
6. The internal surface of the material should be homogeneous. 
7. The internal surface should be capable of modification to provide a range of 
surface functionalities. 
8. Packing materials should be chemically inert under all conditions of pH and 
eluent composition. 
9. The physico-chemical characteristics of the material should be reproducible from 
batch to batch and from manufacturer to manufacturer. 
10. The material should be readily available and relatively inexpensive, and its 
chemical behavior should be well understood. 
There are four different column s are available 
A.Guard Columns:   
These columns are placed anterior to the separating column. This serves as a 
protective factor that prolongs the life and usefulness of the separation column. They 
are dependable columns designed to filter or remove. 
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1)  Particles that clog the separation column.  
2) Compounds and ions that could ultimately cause "baseline drift", decreased 
resolution, decreased sensitivity, and create false peaks. 
3) Compounds that may cause precipitation upon contact with the stationary or 
mobile phase. 
 B. Derivatizing Columns:  
Pre- or post-primary column derivatization can be an important aspect of the 
sample analysis. Reducing or altering the parent compound to a chemically related 
daughter molecule or fragment elicits potentially tangible data which may 
complement other results or prior analysis19. 
C. Capillary Columns:  
Advances in HPLC led to smaller analytical columns. Also known as micro 
columns, capillary columns have a diameter much less than a millimeter and there 
are three types: open-tubular, partially packed, and tightly packed. They allow the 
user to work with nanoliter sample volumes, decreased flow rate, and decreased 
solvent volume usage which may lead to cost effectiveness.  
D. Fast Columns:  
One of the primary reasons for using these columns is to obtain improved 
sample throughput (amount of compound per unit time). For many columns, 
increasing the flow or migration rate through the stationary phase will adversely 
affect the resolution and separation. Therefore, fast columns are designed to 
decrease time of the chromatographic analysis without forsaking significant 
deviations in results20. 
E. Preparatory Columns: 
  These columns are utilized when the objective is to prepare bulk (milligrams) 
of sample for laboratory preparatory applications. A preparatory column usually has 
a large column diameter which is designed to facilitate large volume injections into 
the HPLC system. 
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Types Of Column Packing: 
 Pellicular 
 Porous particle 
Pellicular: 
           The former consist of spherical, non porous, glass or polymer beads with 
typical diameter 30 to 40 micrometer. 
Porous particle: 
           The particles are composed of silica, alumina, and synthetic resin polystyrene 
divinyl benzene or ion exchange resin.                                 
5. DETECTORS:  
The detector converts a change in the column effluent into an electrical 
signal that is recorded by the data system. There are different types of detectors used 
in HPLC. Liquid chromatographic detectors are of two basic types.  
 Bulk Property detectors respond to a mobile-phase bulk property, such as 
refractive index, dielectric constant, or density. In contrast, solute property detectors 
respond to some property of solutes, such as UV absorbance, fluorescence, or 
diffusion current, that is not possessed by the mobile phase. 
A) Refractive Index Detector: The detection principle involves measuring of the 
change in refractive index of the column effluent passing through the flow-cell.  The 
greater the RI difference between sample and mobile phase, the larger the imbalance 
will become. Thus, the sensitivity will be higher for the higher difference in RI   
between sample and mobile phase. On the other hand, in complex mixtures, sample 
components may cover a wide range of refractive index values and some may 
closely match that of the mobile phase, becoming invisible to the detector21. 
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B) UV Detector:  In these systems detection depends on absorption of UV ray 
energy by the sample. They are capable to detect very wide range of compounds. 
The sensitivity ranges till microgram quantity of estimation. 
C) PDA Detector: These are detectors which follow principle similar to UV 
detectors but the only advantages are higher sensitivity and measure the entire 
absorption range i.e.  It gives scan of entire spectrum. 
D) Evaporative Light Scattering Detector (ELSD):  In the ELSD, the mobile 
phase enters the detector is evaporated in a heated device and the remaining solute is 
finally detected by the way it scatters light. The intensity of the light scattered from 
solid suspended particles depends on their particle size. Therefore, the response is 
dependent on the solute particle size produced. This, in turn, depends on the size of 
droplets generated by the nebulizer and the concentration of solute in the droplets. 
The droplet size produced in the instrument nebulizer depends on the physical 
properties of the liquid and the relative velocity and flow-rates of the gas and liquid 
stream. The importance of all these parameters emphasizes the need for careful 
design and rigorous optimization of the instrument parts22. 
E) Electro Chemical Detector: This detector is specially suitable to estimate 
oxidisable & reducible compounds .The principle is that when compound is either 
oxidized or reduced, the chemical reaction produces electron flow. This flow is 
measured as current which is the function of type and quantity of compound 
F) Conductivity Detector: conductivity detector measures the conductivity of the 
mobile phase. There is usually background conductivity which must be backed-off 
by suitable electronic adjustments. If the mobile phase contains buffers, the detector 
gives a base signal that completely overwhelms that from any solute usually making 
detection impossible. Thus the electrical conductivity detector is a bulk property 
detector. And senses all ions whether they are from a solute or from the mobile 
phase. 
G) Fluorescence Detectors: Fluorescence detectors are probably the most sensitive 
among the existing modern HPLC detectors. It is possible to detect even a presence 
of a single analyte molecule in the flow cell.  Typically, fluorescence sensitivity is 
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10 -1000 times higher than that of the UV detector for strong UV absorbing 
materials. Fluorescence detectors are very specific and selective among the others 
optical detectors. This is normally used as an advantage in the measurement of 
specific fluorescent species in samples23. 
H) Mass Spectrometric Detection:  The use of mass spectrometer for hplc 
detection is becoming common place, despite the high cost of such detector and 
need for a skilled operator. A mass spectrometer can facilitate hlpc method 
development and avoid common problem by 
 Tracking and identifying individual peaks in the chromatogram between 
experiments 
 Distinguishing compounds of interest from minor compounds or 
interferences. 
 Recognizing unexpected and overlapping interference peaks to avoid a 
premature finish to method development. 
Temperature: 
 Room temperature is the first choice. Elevated temperatures are sometimes 
used to reduce column pressure are enhancing selectivity. Typically, temperatures in 
excess of 600 C are not used24. 
Retention Time: 
Due to a number of samples assayed in the course of preformulation study, it 
is advisable to have as short a retention time as far as possible. However, the 
retention time should be long enough to ensure selectivity. While choosing the 
optimum mobile phase, considerations should be given to the retention time of 
degradation products. So that these compounds do not elute in the solvent front and 
remain in the column. 
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Fig 1.7.1 Block Diagram Of HPLC 
1.8 APPLICATIONS OF HPLC: 
1.0 Preparative HPLC refers to the process of isolation and purification of 
compounds. This differs from analytical HPLC, where the focus is to obtain 
includes identifications, quantification, and resolution of a compound. 
1. Chemical separations can be accomplished using HPLC by utilizing the 
fact that certain compounds have different migration rates given a particular 
column and mobile phase. Thus the chromatography can separate 
compounds from each other using HPLC; the extent or degree of separation 
is mostly determined by the choice of stationary phase and mobile phase25. 
2. Purification refers to the process of separating or extracting the target 
compound from other (possibly structurally related) compounds or 
contaminants. Each compound should have a characteristic peak under 
certain chromatographic condition. The migration of the compounds and 
contaminants through the column need to differ enough so that the pure 
desired compound can be collected or extracted without incurring any other 
undesired compound. 
3. Identification of the compounds by HPLC is a crucial part of any HPLC 
assay. The parameters of this assay should be such that a clean peak of the 
known sample is observed from the chromatograph. The identifying peak 
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should have a reasonable retention time and should be well separated from 
extraneous peaks at the detection levels, in which the assay would be 
performed. 
4. Quantification of compounds by HPLC is the process of determining the 
unknown concentration of a compound in a solution. It involves injecting a 
series of known concentration of the standard compound solution onto the 
HPLC for detection.  
5. The chromatograph of these known concentrations will give a series of peaks 
that correlate to the concentration of the compound injected26. 
ADVANTAGES:  
 HPLC separations can be accomplished in a matter of minutes, in some 
cases, even in  seconds. High resolution of complex sample mixture into individual 
components can be obtained. 
 Rapid growth of HPLC is also because of its ability to analyse substances that 
are unsuitable for gas liquid chromatographic (GLC) analysis due to non-
volatility or thermal-instability. 
 Quantitative analysis is easily and accurately performed and errors of less than 1 
%   are common to most HPLC methods. 
 Depending on sample type and detector used it is frequently possible to measure 
10-9 g or 1 ng of sample. With special detectors, analysis down to 10-12 g has 
been reported27. 
DISADVANTAGES: 
 HPLC instrumentation is expensive and represents a major investment for many 
laboratories. 
 It requires a proficient operator to handle the instrument. 
 HPLC cannot handle gas samples. 
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 HPLC is poor identifier. It provides superior resolution but it does not provide 
the information that identifies each peak. 
 Sample preparation is often required. 
 Only one sample can be analyzed at a time. 
 Finally there is at present time no universal and sensitive detector.  
1.9 GUIDELINES FOR ANALYTICAL METHOD VALIDATION: 
For pharmaceutical method guidelines are prescribed by  
 United States Pharmacopoeia (USP) 
 Food and Drug Administration (FDA)  
 World Health Organization (WHO) 
 International Conference on Harmonization (ICH) 
 These Guidelines provide a framework for performing validation. In general, 
methods for routine analysis, standardization or regulatory submission must include 
studies on specificity, linearity, accuracy, precision, range detection limit, 
quantitations limit and robustness28. 
United States Pharmacopoeia (USP) : 
 USP defines analytical method validation as “The process by which it is 
established by laboratory studies that performance characteristics of method meet 
the requirement for intended analytical application” 
Food and drug Administration (FDA): 
 FDA defines validation as “Establishing documented evidence, which 
provides a high degree of assurance that a specific process will consistently produce 
meeting its pre- determined specification and quality attributes”. 
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World Health Organization (WHO) : 
 WHO defines validation as “Process of providing documented evidences that 
a system /procedure dose what it is supposed to do precisely and reliably”. 
Objective of Validation: 
 The primary objective of validation is to form a basis for written 
procedures for production and process control which are designed to assure 
that the drug products have the identity, strength, quality and purity they 
purport or are represented to process. Quality, safety and efficacy must be 
designed and built into the products. Each step of the manufacturing process 
must be controlled to maximize the probability that the finished product 
meets all quality and design specifications29. 
Types of Validation:  
 Prospective Validation: This is performed for all new equipments, 
products and processes. It is a proactive approach of documenting the 
design, specifications and performance before the system is operational. This 
is t he most defendable type of validation. 
 Concurrent Validation: This is performed in two instances, i.e., for 
existing Equipment, verification of proper installation along with specific 
Operational tests is done. In case of an existing, infrequently made 
Product, data is gathered from at least three successful trials30. 
Retrospective Validation:  
 This is establishing documented evidence that the Process is performed 
satisfactory and consistently over time, based on review and analysis of 
historical data. The source of such data is production and QA/QC records. 
The issues to be addressed here are changes to equipment, process, 
specifications and other relevant changes in the past. 
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ANALYTICAL METHOD VALIDATION: 
         Analytical monitoring of a pharmaceutical product or of specific 
ingredients within the product is necessary to ensure its safety efficacy 
throughout all phases of its shelf life. Such monitoring is in accordance 
with the specifications elaborated during product development. Analytical 
validation is the corner stone of process validation without a proven 
measurement system it is impossible to confirm whether the manufacturing 
process has done what it purports to do. All new methods developed are 
validated. 
Steps followed for validation procedures  
1. Proposed protocols or parameters for validations are established. 
2. Experimental studies are conducted.  
3. Analytical results are evaluated 
4. Statistical evaluation is carried out.  
5. Report is prepared documenting all the results.  
Objective: 
           The objective of validation of an analytical procedure is to 
demonstrate that it is suitable for its intended purpose. According to ICH, 
typical analytical performance characteristics that should be considered in the 
validation of the types of methods are: 
 Accuracy 
 Precision 
 Specificity 
 Detection limit 
 Quantitation limit 
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 Linearity and Range 
 Ruggedness 
 Robustness 
 System suitability 
International conference on Harmonization (ICH) : 
 ICH is tripartite agreement between European community, USA and Japan. 
Its purpose is to provide a forum for constructive dialogue between regulatory 
authorities and Pharmacy industry on real and perceived differences in technical 
requirements for product registration in European community USA and Japan31. 
 Objective is lying down of minimum standards applicable uniformly, 
irrespective of where the product is manufactured or marketed in the three regions. 
The ICH documents give guidance on the necessity for revalidation in the following 
circumstances. 
 Changes in the synthesis of the drug substances 
 Changes in the composition of the drug product and  
 Changes in the analytical procedures               
 Although there is general agreement about what type of studies should be 
done, there is great diversity in how they are performed. The literature contains 
diverse approaches to performing validations. This approach should be viewed with 
the understanding that validation requirements are continually changing and vary 
widely, depending on the type of drug being tested the stage of drug development 
and the regulatory group that will review the drugs application. For our purposes, we 
will discuss validation studies as they apply to Chromatography method, although 
the same principles apply to other analytical technique32. 
 The process of validating a method cannot be separated from the actual 
development of the method conditions, because the developer will not know whether 
the method conditions are acceptable until validation studies are performed. 
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 The development and validation of a new analytical method may therefore be 
an iterative process. Results of validation studies may indicate that a change in the 
procedure is necessary, which may then require revalidation. During each validation 
study, key method parameters are determined and the n used for all subsequent 
validation steps. To minimize repetitious studies and ensure that the validation data 
are generated under conditions equivalent to the final procedure, we recommend the 
following sequence of studies.  
1.10 METHOD VALIDATION PARAMETERS:  
 They have been defined in different working groups of national and 
international committees and are described in literature. The parameters as defined 
by the ICH and by other organization and authors are summarized below. They are  
A.SPECIFICITY / SELECTIVITY:  
 Specificity, which can be defined as the ability to measure accurately the 
concentration of analyte in the presence of all other sample materials. If specificity 
is not assured, method accuracy, precision and linearity all are seriously 
compromised. Assuring specificity is the first step in developing and validating good 
method. The determination of method specificity can be achieved in two ways, first 
most desirable all potential interfering compounds can be tested to demonstrate their 
separation from the peaks of interest with a specified Resolution Second method for 
achieving specificity is the use of selective detector, especially for co-eluting 
compounds, for e.g. a selective detector (e.g. electrochemical, radioactive will 
respond to some compounds but not others Specificity of a developed method often 
is difficult to ensure. However, there are a number of techniques that can be used in 
method validation experiments that will increase confidence in specificity33 
1. Spiking of known interferants. 
2. Sample degradation studies. 
3. Peak collection with subsequent analysis by other techniques. 
4. Use of another chromate graphic method. 
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5. Changing the conditions of the HPLC method (alternative. solvents or 
different gradient slopes).  
B) PRECISION: 
Precision can be de fined as “the degree of agreement among the individual 
test results when the Procedure is applied repeatedly to multiple samplings of 
homogenous sample  
ICH divides Precision into three types  
1. Repeatability. 
2. Intermediate precision 
3. Reproducibility  
Repeatability 
Repeatability is the precision of a method under same operating conditions 
over a short period of time. This is measured by the sequential repetitive injections 
of the same homogenous sample (typically, 10 or more times), followed by aver 
raging of the peak height (or) peak area values and determination of relative 
standard deviation of all injections. 
Intermediate precision: 
Is the agreement of complete measurements (including standards) when the 
same method is applied many times within the same laboratory. This can include full 
analysis on different days, Instruments or analysts, but would involve multiple 
preparations of samples and standards34. 
Reproducibility: 
Examines the Precision between laboratories and is often determined in 
collaborative studies or method transfer experiments. Precision often is expressed by 
the S.D and RSD data set. 
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C) ACCURACY: 
           The accuracy of a measurement is defined as the closeness of measured value 
to the true value. In a method with a high accuracy, a sample (“Whose true value” is 
known) is analyzed and the measured value should ideally be identical to the true 
value. Typically accuracy is represented and determined by recovery studies but 
there are three ways to determine accuracy  
1. Comparison to a reference standard 
2. Recovery of analyte spiked into blank matrix. 
3. Standard addition of analyte.  
Comparison to Reference Standard: 
            Determining accuracy by direct comparison to a reference standard (a 
standard reference material is the preferred technique for an analyte.(e.g.; Purified 
drug substance)that is not in a complex sample matrix. if the analyte is widely 
assayed, a certified standard may be obtained  from an external source as the 
national institute for standards and technology (NIST).  
              Accuracy determination for an hplc method should be carried out with a 
minimum of nine measurements using at least three concentrations. (Include 
separate weighing plus preparation for each sample).This approach minimizes any 
variability and or bias in sample preparation technique and analysis or one sample at 
only one concentration. An example would be three replicate measurements each of 
three replicate measurements each of three different concentration preparations. All 
nine values are averaged and used for the final accuracy determination35. 
Analyte recovery: 
                     It can be determined by analyte reference standard is added to a blank 
matrix (sometimes called a placebo) at various levels the blank matrix could take 
many forms. For e.g. in an analysis of a drug formulation it would include all 
formulation ingredients except analyte to be measured.  
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                The recovery at each level is determined by comparison to the known 
amount added. For major component assay, spiked levels typically should be at 
50%, 75%, 100%, 125% and 150% of the level is expected r the analyte in a normal 
assay. A minimum o three replicate measurements should be perfumed at each level. 
Method of standard addition: 
                  In this method, known amounts of an analyte are spiked at different 
levels into a sample matrix that already contains some (unknown) quantity of the 
analyte. The concentration of analyte in the original sample may then be determined 
mathematically. In general, for standard addition of, a good approach is to add 25, 
50 and 100% of the expected analyte concentration to the matrix in different 
experiments. The unspiked sample and each of the spiked samples should be 
analyzed (usually in triplicate) and the measured amounts reported vs. the amount 
added. This method is used when it is difficult or impossible to prepare blank matrix 
without analyte. An example would be the analysis of insulin in a normal blood 
sample, where background levels of insulin always are present36 . 
D) LINEARITY: 
The linearity of a method is a measure of how well a calibration plot of 
response Vs concentration approximates a straight line. Linearity can be assessed by 
performing single measurements at several analyte concentrations. The data are then 
processed through linear least square regression. The resulting plot on slope, 
intercept and correlation coefficient gives the desired information on linearity. A 
linearity correlation coefficient above 0.999 is acceptable for most methods, 
especially for a major component in assay methods, methods with linearity poorer 
than this may have to be treated as non-linear and use more complicated multipoint 
calibrations or non linear response modeling37. 
The least squares method of determining linearity can have serious short 
comings if response must be measured over one or more orders of magnitude. Here 
the slope, intercept, and correlation coefficient can unduly influenced by data at low 
or high concentrations. Small changes in the calculated value of either the slope or 
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intercept can lead to errors in estimating the true value for a sample, Therefore a 
better method of assessing linearity is desired. 
A generally superior method for determining method linearity over wide 
concentration ranges. This approach involves determining the response factor at 
each measured concentration and plotting this response factor vs. analyte 
concentration. 
RF=DR/C 
Where DR is the detector response and C is the concentration of the analyte. 
Ideally the response factor should be independent of concentration if the method is 
truly “linear” the response factor is independent of concentration for ranges of 1.2 to 
10.0µg/ml. At lower concentration this relationship deviates, and the assumed 
linearity no longer holds. 
E) RANGE: 
The range of a method can be defined as the lower and upper concentrations 
for which the analytical method has adequate accuracy, precision, and linearity, 
while a desired concentration on range is often known before starting the validation 
of a method, the actual working range results from data generated during validation 
studies. The range of concentration examination will depend on the type of method 
and its use. For a major component assay, the concentration range should encompass 
values expected in samples to be measured. A good strategy is to perform at 50%, 
75%, 100%, and 125% and 150% of target levels. This range also has potential to 
demonstrate that the method is linear outside the limits of expected use. (Typically 
90 to 110%) 
Major component assays of pharmaceuticals often are used to measure 
content uniformity for a dosage unit. The USP definition of content uniformity 
allows a single value to deviate from the target by as much as ±25% even if the 
assay is expected to fall within ±5 to 10% of the target value. Furthermore, drug 
stability data (especially those in accelerated studies) can generate values outside the 
anticipated specification range. This requires that the validation extend well beyond 
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the expected specification level or Target values for the assay of unstressed product 
.In case where the sample concentration is above the calibration range, dilution of 
the sample to the appropriate concentration is recommended38. 
Methods for the determining impurities, degradants and other related 
substances can generate concentrations that vary over several orders of magnititude, 
depending on method sensitivity. A recommended range to be examined in 
validation studies in Pharmaceutical and related samples should start at the limit of 
quantitation and extend up to at least 5% of the concentration of the major 
component. Measurements beyond this range typically are not needed since related 
substances are rarely tolerated at higher levels in a raw materials or finished product 
.For application to other types of sample, this recommended range may need to be 
adjusted: however, the key point is to validate the expected range of all potential 
samples39. 
F) LIMIT OF DETECTION (LOD): 
 LOD is defines as lowest concentration of analyte that can be detected, but 
not necessarily quantified, by the analytical method. The limit of detection is the 
point at which a measured value is larger than the uncertainty associated with it. In 
chromatography the detection limit is the injected amount that results in a peak with 
a height at least twice or three times as high as the baseline noise level. Usually 
expressed as concentration of analyte generating an instrument response and is 
equivalent to three times the noise (S / N ratio~3). 
Based on S / N ratio: 
 This approach can be applied to analytical procedures that exhibit baseline 
noise. Determination of the S / N ratio is performed by comparing measured signals 
from samples and establishing the minimum concentration at which the analyte can 
be reliably detected. The S / N ratio between 3 or 2:1 is generally considered 
acceptable for estimating the detection limit. 
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G) LIMIT OF QUANTIFICATION (LOQ): 
 LOQ is defined as the lowest concentration of analyte that can be determined 
with acceptable accuracy and precision by the analytical method. Usually expressed 
as concentration of analyte generating an instrument response and is equivalent to 
ten times the noise (S / N ratio~10). Several approaches for determining the 
detection limit are possible, depending on whether procedure is non-instrumental or 
instrumental 
Based on Signal-to-Noise ratio: 
  This approach can be applied to analytical procedures that exhibit baseline 
noise. Determination of the signal-to-noise ratio is performed by comparing 
measured signals from with known low concentration of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can be 
reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally considered 
acceptable for estimating the detection limit40. 
 The LOD and LOQ values determined during method validation are affected  
by the separation conditions : columns, reagents, and especially instrumentation and 
data systems .Instrumental changes .Particularly  pumping systems  and detectors ,or 
the use of  contaminated reagents  can results  in large changes in S/N ratio . 
H) ROBUSTNESS:  
It can be defined as measure of its capacity to remain unaffected by small but 
deliberate variations in method parameters. Robustness tests examine the effect 
operational parameters have on the analysis results. Factors internal to the method: 
mobile phase pH, mobile phase composition, temperature, flow rate, injector / 
detector temperatures etc. the robustness of a method is its ability to remain 
unaffected by the small changes in the parameters such as percent organic content 
and pH of the mobile phase, buffer concentration, temperature, flow rate and 
injection volume. These method parameters may be evaluated one factor at a time or 
simultaneously as part of factorial experiment. Obtaining data on the effects of these 
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parameters may allow a range of acceptable values to be included in the final 
method procedure41. 
Attention to the foregoing considerations will significantly improve the 
quality of the final method .The one exception, however, is the column. There is the 
possibility that a column from a different manufacturing lot will not give 
reproducible retention of all sample components, possibly resulting in an 
unacceptable separation .For this reason it is important to evaluate columns from at 
least three different columns can be obtained .if significant lot to lot variations in 
sample retention are observed ,appropriate  steps should be taken to avoid future 
problems .One approach is to stockpile enough columns from a good batch for all 
future  uses of the method .Another approach is to determine whether small changes 
in condition (%B,temperature-pH,etc) can be used to minimize or correct any 
undesirable changes in retention from lot to lot. 
SYSTEM SUITABILITY PARAMETERS 
Prior to the analysis of samples each day, the operator must establish that the 
HPLC system and procedure are capable of providing data of acceptable quality 
.This is accomplished withSystem suitability experiments and can be defined as tests 
to ensure that the method can generate results of acceptable accuracy and precision. 
The Requirements for systems suitability are usually developed after method 
development and validation have been completed .The criteria selected will based on 
the actual performance of the method as determined during its validation .For eg, if 
sample retention times form part of the system suitability criteria, their validation 
can be determined .System suitability might then require that retention times fall 
within ±3 SD range during routine performance of the method42. 
The USP defines parameters that can be used to determine systems suitability 
prior to analysis. These parameters include plate number (N), Tailing factor k and 
Resolution (Rs) and Relative Standard Deviation (RSD) of Height or peak area for 
repetitive injections .Typically, at least two of these criteria are required to 
demonstrate system suitability for any method The RSD of Peak height or area of 
five repetitive injections of a standard solution is normally accepted as one of the 
standard criteria .For an assay method of a major component. The RSD should 
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typically be less than 1% for these repetitive injections .For the measurements of a 
compound at atrace3 levels, such as an impurity standard run at or near the limit of 
quantitation, a higher RSD (5 to15%) is acceptable43. 
Commonly used system suitability parameters are as follows: - 
Retention Time (RT):  
Retention time is the time of elution of peak maximum after injection of compound. 
Theoretical Plates (N):  
 It is also called as column efficiency. A column can be considered as being 
made of large number of theoretical plates where distribution of sample between 
liquid –liquid / solid –liquid phase occurs. The number of theoretical plates in 
column is given by relationship44.               
N=16 (tR / w)
 2 
 Where‘tR’ is the retention time and ‘w’ is the width at the base of peak. 
Theoretical Plates should be more than 2000 
 
                                            Fig2. 5-Theoretical Plates                                        
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How many peaks can be located per unit run-time of the chromatogram, 
where tR is the retention time for the sample peak and W is the peak width? 
N is fairly constant for each peak on a chromatogram with a fixed set of 
operating conditions. H, or HETP, the height equivalent of a theoretical plate, 
measures the column efficiency per unit length (L) of the column. Parameters which 
can affect N or H include Peak position, particle size in column, flow-rate of mobile 
phase, column temperature, viscosity of mobile phase, and molecular weight of the 
Analyte45. 
The theoretical plate number depends on elution time but in general should 
be > 2000.  
Resolution (R): 
 It is a function of column efficiency and is specified to ensure that closely 
eluting compounds are resolved from each other to establish the general resolving 
power of the system. For the separation of the two components in mixture the 
resolution is determined by equation.     
R  = 2  ( t2 - t1 ) / ( w2 + w1 ) 
Where t2 and t1 are the retention time of second and first compounds 
respectively, where as W1 and W2 are the corresponding widths at the bases of peak 
obtained by extrapolating straight sides of the peaks to baselines. R’ should be more 
than 2 between peak of interest and the closest eluted peak   for potential 
interferences46 (impurities, Excipients, degradation products or internal standard) 
 
Fig.2.6  Resolution 
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For reliable Quantitation, well-separated peaks are essential for Quantitation.  
Recommendations: 
 R of > 2 between the peak of interest and the closest potential interfering 
peak (impurity, excipient, degradation product, internal standard, etc.) are desirable. 
Tailing Factor (T): 
It is a measure of peak symmetry, and is unity for perfectly symmetrical 
peaks and its value increases as tailing become more pronounced. 
T= W0.05 / 2F 
 Where W0.05 is the width of peak at 5% height and ‘F’ is the distance from 
the peak maximum to the leading edge of the peak height forms the baseline. 
Tailing factor should be less than 2                                   
 
Fig.2.7- Tailing Factor 
The accuracy of Quantitation decreases with increase in peak tailing because 
of the difficulties encountered by the integrator in determining where/when the peak 
ends and hence the calculation of the area under the peak. Integrator variables are 
preset by the analyst for optimum calculation of the area for the peak of interest47. 
Recommendations    T of ≤ = 2 
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Capacity Factor (k):  
The capacity factor is a measure of the degree of retention of an analyte 
relative to an unrestrained peak, where tR is the retention time for the sample peak 
and to be the retention time for an unrestrained peak
48. 
 
Fig.2.8- Capacity factor 
k' = (t R- t0) / t 0 
Recommendations: 
            The peak should be well-resolved from other peaks and the void volume. 
Generally the value of k' is > 2. 
Precision / Injection repeatability (RSD) of < 1% for ‘n’ > 5 is desirable. 
Selectivity (α), Separation factor:  
It is a measure of peak spacing and expressed as, 
α = (k’2 / k’1). 
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Table 1.11 System Suitability Parameters and Recommendations 
Parameter Recommendation 
Capacity Factor (k’) The peak should be well-resolved from other peaks and the void 
volume, generally k’>2.0. 
Repeatability RSD ≤ 1% for N ≥ 5 is desirable. 
Relative retention Not essential as long as the resolution is stated. 
Resolution (Rs) Rs of>2 between the peak of interest and the closest 
elutingpotentialinterferent (impurity, excipient, degradation 
product, internal standard, etc.) 
Tailing factor (T) T of ≤2 
Theoritical plates (N) N ≤ 2000 
 
1.12 STATISTICAL ANALYSIS: 
 The consistency and suitability of the developed method are substantiated 
through the statistical analysis like standard deviation, relative standard deviation 
and theoretical plates per meter49. 
For Accuracy: 
Standard deviation =  = 
1
)xx(
2
i


n
 
Where, x = sample.  
xi = mean value of samples.  
n = number of samples. 
Relative Standard Deviation = /xi × 100 
Molar extinction coefficient (mol-1 cm-1) =A/C × L 
Where, A= Absorbance of drug. 
 C= concentration of drug. 
 L= Path length. 
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Sandell’s sensitivity (µg / cm2/ 0.001 absorbance units) =   C/A×0.001 
Where, C= concentration of drug 
            A= Absorbance of drug    
Unit = μg / cm2 = 0.001 absorbance) 
Coefficient of variance (σ) :  
Coefficient of variance= ∑(x-x‾)2/ n-1                      
Régressions équation,       y = a+bx 
Slope = y/x 
Where, x = Concentration 
            y= Absorbance 
            a=Intercept  
Limit of detection (DL):  
Limit of Detection = 3.3×\ S   
Units - (μg / ml) 
Where,  = the standard deviation of the response. 
             S = the slope of the calibration curve. 
The slope S may be estimated from the calibration curve of the analyte. 
The estimation of  may be carried out in a variety of ways. 
Limit of quantitation (QL):  
Limit of Quantitation = 10×\ S 
Unit- (μg / ml) 
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Where,    = the standard deviation of the response 
               S = the slope of the calibration curve.  
The slope S may be estimated from the calibration curve of the analyte.  
The estimation of  may be carried out in a variety of way. 
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2. LITERATURE REVIEW 
1. P. N. S Pai  et., al. 46 reported a precise method  in which Tinidazole and 
diloxanide furoate have been simultaneously determined by spectrometric 
methods  For the proposed method all the chemicals of analytical reagent grade, 
solvents of HPLC grade and distilled water (Millipore) were used. The LC 
system consisted of LC-10AT pump (Shimadzu), SS Wakosil-II C-18, 250×4.6 
mm, 5 μm column, Rheodyne injector equipped with a 100 μl sample loop and 
UV detector (Shimadzu SPD-10A VP) set at 282 nm. The output signal was 
monitored and integrated using CZ-RA software (Shimadzu).The standard 
solution of diloxanide furoate 500 μg/ml and tinidazole 500 μg/ml were prepared 
separately by dilution of tinidazole and diloxanide furoate respectively in mobile 
phase of acetonitrile, methanol and 0.2M potassium dihydrogen phosphate pH 
5.0 in the ratio 2:3:2. The retention time for tinidazole and diloxanide furoate at 
a flow rate of 1ml/min were recorded as 3.4 and 5.2 min respectively. From the 
respective peak areas obtained in standard and sample chromatogram. 
2. P. Parinoo  et., al 47  A differencial  spectrophotometric procedure has been 
developed for the simultaneous determination of Tinidazole (TD) and 
Diloxanide furoate (DF) in tablet preparations. The method comprised the 
measurement of absorbance of a solution of the tablet extract in pH 2.0 buffer 
solution relative to that of an equimolar solution in pH 13.0 buffer at the 
wavelengths of 282nm and 240nm. The presence of identical isoabestic points 
for pure drug samples and tablet extract solutions indicated tho non-interference 
of excipients in the absorption at these wavelengths. The compliance of Beer's 
Law was obtained in the concentration range of 20–40μg/ml for TD and DF at 
theee wavelengths. 
3. Chiranjeevi bodepudi et.,al.48 was reported  a  precise and feasible high-
performance liquid chromatographic (HPLC) method for the analysis of the 
Fluconazole and Tinidazole in a combined tablet dosage form has been 
developed. The analysis was carried out on a Kromasil stainless steel C18 (250 x 
4.6 mm, 5 μ) reversed-phase column, using a mixture of Acetonitrile: Water 
(55:45%v/v) as the mobile phase using a low pressure gradient mode with flow 
Chapter 2 Literature Review 
Dept. of Pharmaceutical Analysis 45 J.K.K. Nattraja College of Pharmacy 
rate at 1ml/min. The injection volume was 20μl..The retention time of the drug 
was 2.5 for Fluconazole and 3.1 for Tinidazole. The method produced linear 
responses in the concentration range of 10 to 50μg/ml for both Fluconazole and 
Tinidazole. The Tailing factors of Fluconazole and Tinidazole were found to be 
1 and 1.3 respectively. The method was found to be applicable for determination 
of the drug in tablets. 
4. Nada Sayed Abdelwahab et.,al 49 Was reported  a work which is concerned 
with development and validation of chromatographic and spectrophotometric 
methods for analysis of Mebeverine HCl (MEH), Diloxanide furoate (DF) and 
Metronidazole (MET) in  tablets spectrophotometric and RP-HPLC methods 
using UV detection. The developed spectrophotometric methods depend on 
determination of MEH and DF in the combined dosage form using the 
successive derivative ratio spectra method which depends on derivatization of 
the obtained ratio spectra in two steps using methanol as a solvent and measuring 
MEH at 226.4-232.2 nm (peak to peak) and DF at 260.6-264.8 nm (peak to 
peak). While MET concentrations were determined using first derivative (1D) at 
λ = 327 nm using the same solvent. The chromatographic method depends on 
HPLC separation on ODS column and elution with a mobile phase consisting 
water: methanol: triethylamine (25: 75: 0.5, by volume, orthophosphoric acid to 
pH =4). Pumping the mobile phase at 0.7 ml min-1 with UV at 230 nm. Factors 
affecting the developed methods were studied and optimized, moreover, they 
have been validated as per ICH guideline and the results demonstrated that the 
suggested methods are reproducible, reliable and can be applied for routine use 
with short time of analysis. Statistical analysis of the two developed methods 
with each other using F and student's-t tests showed no significant difference 
5. Divya Patel et., al 56 was developed precise and accurate Stability indicating RP-
HPLC method for simultaneous estimation of Diloxanide Furoate and 
Ornidazole in Their Combined Dosage Form has been developed. The separation 
was achieved by LC- 20 AT C18 (250mm x 4.6 mm x 2.6 μm) column and 
Buffer (pH 4.5): Acetonitrile (40:60) as mobile phase, at a flow rate of 1 ml/min. 
Detection was carried out at 277 nm. Retention time of Ornidazole and 
Diloxanide Furoate were found to be 4.620 min and 7.633 min, respectively. The 
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method has been validated for linearity, accuracy and precision. Linearity 
observed for Ornidazole 5-15 μg/ml and for Diloxanide Furoate 7.5-22.5 μg/ml. 
The percentage recoveries obtained for Ornidazole and Diloxanide Furoate were 
found to be in range of 100.88 ± 0.60 and 100.85± 0.20 respectively. 
6. Hiradeve S.M et.,al 57  had did a reverse phase high performance liquid 
chromatography method was developed for the simultaneous estimation of 
diloxanide furoate and metronidazole in formulation. The separation was 
achieved by octadecyl C8 column and a mixture of methanol: acetonitrite: 
0.05M phosphate buffer at pH 4.0 (45:25:30 v/v) as eluent, at a flow rate of 1 
ml/min. detection was carried out at 277 nm. Quantitation was done by external 
standard method. The retention time of metronidazole and diloxanide furoate 
was found to be 3.28 and 6.42 min, respectively. The method has validated for 
linearity, accuracy and precision. Linearity of metronidazole and diloxanide 
furoate were in the range of 5-50 µg/ml for both the drugs The mean recoveries 
obtained for metronidazole and diloxanide furoate were100.01% and 99.71%, 
respectively 
7. RK Maheshwarin et.,al52 was developed a safe and sensitive method of 
spectrophotometric estimation in the ultraviolet region has been developed using 
1M lignocaine hydrochloride (an economic drug) as a hydrotropic solubilizing 
agent for the quantitative determination of tinidazole, a sparingly water-soluble 
antiprotozoal drug in tablet dosage form. Beer’s law was obeyed in the 
concentration range of 5-25 mg/ml. Lignocaine hydrochloride does not interfere 
above 280 nm. There was more than a six-fold enhancement in aqueous 
solubility of tinidazole in 1M lignocaine hydrochloride solution as compared 
with the solubility in distilled water. Commonly used tablet excipients and 
lignocaine hydrochloride did not interfere in spectrophotometric estimation, 
8. Minal Rohit et.,al53 have been developed a HPTLC method for simultaneous 
determination of clotrimazole and tinidazole in tablet and cream. The developed 
method is more sensitive than the reported method. Chromatographic separation 
was carried out on aluminum-backed silica gel 60 GF254 TLC plates with 
mobile phase comprising of toluene: ethyl acetate: methanol: triethylamine 
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(5.5:1.0:1.0:0.1, v/v). The validated calibration ranges were 200-700 ng/spot 
(r=0.9960 and 0.9960 by height and area respectively) and 500-1750 ng/spot 
(r=0.9990 and 0.9975 by height and area respectively) for clotrimazole and 
tinidazole respectively. Quantitation was achieved with UV detection at λ=220 
nm. 
9. Swati Bantu et.,al 55 was developed in precise and feasible high-performance 
liquid chromatographic (HPLC) method for the analysis of the Fluconazole and 
Tinidazole in a combined tablet dosage form has been developed. The analysis 
was carried out on a Kromasil stainless steel C18 (250 x 4.6 mm, 5 μ) reversed-
phase column, using a mixture of Acetonitrile: Water (55:45%v/v) as the mobile 
phase using a low pressure gradient mode with flow rate at 1ml/min. The 
injection volume was 20µl..The retention time of the drug was 2.5 for 
Fluconazole and 3.1 for Tinidazole. The method produced linear responses in the 
concentration range of 10 to 50μg/ml for both Fluconazole and Tinidazole. The 
Tailing factors of Fluconazole and Tinidazole were found to be 1 and 1.3 
respectively. 
10. Nirav Patel B et.,al 58 research manuscript describes simple, sensitive, accurate, 
precise and repeatable RP-UPLC method for the simultaneous determination of 
Ciprofloxacin HCl (CH) and Tinidazole (TZ) in tablet dosage form. The sample 
was analyzed by reverse phase C18 column (Purospher Star 100×2.1 mm, 2µm) 
as stationary phase and Phosphate Buffer: Acetonitrile (80:20) as a mobile phase 
and pH 3.0 was adjusted by ortho-phosporic acid at a flow rate of 0.3 ml/min. 
Quantification was achieved of Ciprofloxacin HCl at 278.5 nm and of Tinidazole 
at 317.5 nm with PDA detector. The retention time for Ciprofloxacin HCl and 
Tinidazole was found to be 1.71 and 2.22 minute respectively. The linearity for 
Ciprofloxacin HCl and Tinidazole was obtained in the concentration range of 
3.125-43.75 µg/ml and 3.75-52.5 µg/ml with mean accuracies of 99.77% and 
99.75% respectively. 
11. R. Adinarayana et., al54  was developed in precise stability indicating RP-HPLC 
method was developed and validated for the simultaneous determination of 
Tinidazole and Diloxanide furoate in pharmaceutical dosage forms. 
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Chromatography was carried out on kromasil C 18 (150 mm x 4.6 mm, 5 µ 
particle size) column using a mobile phase of phosphate buffer (adjusted to pH 
3.3 with 0.1% orthophosphoric acid): acetonitrile (45:55 % v/v) at a flow rate of 
1.0 ml/min. The analyte was monitored using PDA detector at 278 nm. The 
retention time was found to be 2.443 min and 3.653 min for Tinidazole and 
Diloxanide furoate respectively. The proposed method was found to be having 
linearity in the concentration range of 30-180 µg/ml for Tinidazole and 25-
150µg/ml for Diloxanide furoate respectively. The mean % recoveries obtained 
were found to be 99.7-100.08% for Tinidazole and 99.8-100.02% for Diloxanide 
furoate respectively. 
12. Atul Sayare et.,al50 was developed a simple, accurate and reproducible 
spectrophotometric methods have been developed for the simultaneous 
estimation of norfloxacin and Tinidazole in pharmaceutical dosage forms. The 
first method involves determination using the Vierodt’s Method (Simultaneous 
Equation Method); the sampling wavelengths selected are 273 nm and 319 nm 
over the concentration ranges of 2.5- 20µg/mL and 5-40 µg/mL for Norfloxacin 
and Tinidazole respectively. The second method involves determination using 
the Multicomponent Mode Method; the sampling wavelengths selected are 273 
nm and 319 nm over the concentration ranges of 2.5-20µg/mL and 5-40 µg/mL 
for Norfloxacin and Tinidazole respectively. 
13. Nabil .A .F. Alhemiarya. b et., al51 was developed as two simple sensitive and 
reproducible spectrophotometric methods have been developed for the 
determination of tinidazole either in pure form or in their tablets. The proposed 
methods are based on the reduction of the nitro group to amino group of the 
drug. The reduction of tinidazole was carried out with zinc powder and zinc dust 
and concentrated HCl at 90 ± 5 °C for 15 min in water. Method A is based on 
Schiff's basses reaction used ethyl vanillin reagent and measurement of the 
yellow coloured species (λmax: 470 nm),whereas method B is based on 
oxidative coupling reaction used promethazine hydrochloride reagent and 
sodium hypochlorite oxidation agent in alkaline medium to form red colored 
measurable at 525 nm.The working conditions of both methods have been 
optimized. Regression analysis of Beer ’s law plots showed good correlation in 
Chapter 2 Literature Review 
Dept. of Pharmaceutical Analysis 49 J.K.K. Nattraja College of Pharmacy 
the concentration ranges 5-65 and 2-50 µg ml-1 for methods A and B, 
respectively. The apparent molar absorptivity and Sandell sensitivity values are 
calculated to be 3.214x103 and 1.028x104 l. mol-1 cm -1, and 0.0769 and 
0.0267 µg cm-2,with LOD 0.552 µg ml- 1 and 0.285µg ml-1, LOQ 1.840µg ml-
1 and 0.942µg ml-1, respectively. 
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3. OBJECTIVE AND PLAN OF WORK 
OBJECTIVE 
According to literature survey, various analytical methods like UV, HPLC, 
etc. were reported for the simultaneous analysis of Tinidazole and Diloxaide 
Furoate.  Stability indicating method studies were not available as per the existing 
literature survey. Hence studies were under taken to develop and validate stability 
indicating assay for estimation of these two drugs. It is felt worthwhile to develop a 
simple, rapid, accurate, precise and more economical stability indicating high 
performance liquid chromatographic method for Tinidazole and Diloxanide Furoate 
combination in bulk and its combined dosage form. Some RP-HPLC methods were 
not economical in terms of mobile phase composition, column dimensions and run 
times. Hence there is need for the development of newer method for estimation of 
Tinidazole and Diloxanide Furoate present in tablet to overcome above discussed 
hurdles. 
Develop and validate the stability indicating assay method for Tinidazole and 
Diloxanide Furoate using RP-HPLC technique: 
Hence the present work is aimed to develop and validate the stability 
indicating assay method for Tinidazole and Diloxanide Furoate using RP-HPLC 
technique. The Present study was planned to develop a faster gradient elution for 
estimation of Tinidazole and Diloxanide Furoate. The developed method was 
planned to validate as per ICH and USP guide lines in terms of accuracy, precision, 
specificity, and limit of detection, limit of quantitation, linearity, range robustness. 
PLAN OF WORK 
 Study of physicochemical properties of the drug. 
 Review of literature. 
 Procurement of drug substances and related substances for study. 
 Determination of isobestic point of Tinidazole and Diloxanide Furoate. 
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 Selection of chromatographic conditions like column,mobile phase, and flow 
rate in RP-HPLC. 
 Optimization of the method. 
 Validation of the developed method as per ICH guidelines and conduct 
forced degradation studies. 
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4. DRUG PROFILE 
4.1 TINIDAZOLE  
Structure 
Fig No. 4.1.1 Structure of Tinidazole 
 
Chemical Name  : 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole. 
Molecular Formula : C8H13N3O4s 
Molecular Weight : 247.27 
Melting point : 127-128 °C. 
PKa Value                   : 3.1 (strong basic) 
Drug Category         : Anti protozoal, anti Infective. 
Solubility     : Soluble in most organic solvents, and insoluble in water. 
Description : White powder. 
Storage   : Store at controlled room temperature at 20-25°C. 
Dosage Forms   : Tablets,pills. 
Available dose         : 250mg, 500mg.  
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CLINICAL PHARMACOLOGY 
Mechanism of action    
Tinidazole is an antiprotozoal, antibacterial agent. The nitro- group of 
tinidazole is reduced by cell extracts of Trichomonas. The free nitro- radical 
generated as a result of this reduction may be responsible for the antiprotozoal 
activity. Chemically reduced tinidazole was shown to release nitrites and cause 
damage to purified bacterial DNA in vitro. Additionally, the drug caused DNA base 
changes in bacterial cells and DNA strand breakage in mammalian cells. The 
mechanism by which tinidazole exhibits activity against Giardia and Entamoeba 
species is not known. 
Pharmacokinetic Parameter: 
Bioavailability          :          50 to 90% 
Metabolism           :          Hepatic (CYP2C19, CYP3A4) 
Half-life           :          12-14 hours 
Excretion           :          20-25% Renal 
                                             12% Faecal 
Contraindications        
Contraindications for treatment with olmesartan include biliary obstruction 
(BNF). Another major contraindication is pregnancy; reports in the scientific 
literature reveal fetal malformations for pregnant women taking sartan-derived 
drugs.Tinidazole may enhance the effect of warfarin and other coumarin 
anticoagulants, resulting in a prolongation of prothrombin time. 
Drug Interactions: 
 In patients with a previous history of hypersensitivity to tinidazole  reported 
reactions have ranged in severity from urticaria to Stevens-Johnson syndrome. 
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 During first trimester of pregnancy   
 In nursing mothers: Interruption of breast-feeding is recommended during 
tinidazole therapy and for 3 days following the last dose          
 CYP3A4 Inducers and Inhibitors: Simultaneous administration of tinidazole with 
drugs that induce liver microsomal enzymes, i.e., CYP3A4 inducers such 
as phenobarbital, rifampin, phenytoin, and fosphenytoin (a pro-drug of 
phenytoin), may accelerate the elimination of tinidazole, decreasing the plasma 
level of tinidazole. Simultaneous administration of drugs that inhibit the activity 
of liver microsomal enzymes, i.e., CYP3A4 inhibitors such ascimetidine and 
ketoconazole, may prolong the half-life and decrease the plasma clearance of 
tinidazole, increasing the plasma concentrations of tinidazole. 
 Tinidazole may enhance the effect of warfarin and other coumarin 
anticoagulants, resulting in a prolongation of prothrombin time. 
SIDE EFFECTS:  
 Fever, chills, body aches, flu symptoms. 
 Numbness, burning pain, or tingly feeling. 
 Seizure (convulsions). 
 Vaginal itching or discharge. 
 Nausea, vomiting, loss of appetite, indigestion. 
 Constipation, diarrhea, stomach cramps. 
 Feeling weak. 
USES:  
 Tinidazole is an antibiotic that fights bacteria in the body. 
 Tinidazole is used to treat certain infections caused by bacteria, such as infection 
of the intestines or vagina. It is also used to treat certain sexually transmitted 
infections. 
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 Tinidazole may also be used for purposes other than those listed in this 
medication guide 
 Is used to treat certain types of vaginal infections (bacterial vaginosis, 
trichomoniasis). It is also used to treat certain types of parasite infections 
(giardiasis, amebiasis).  
BRAND NAMES:  
Brand name Manufacturer Strength Type of dosage 
form  
Fasigyn Pfizer 500 mg Tablets 
Tindamax Mission pharma 250mg, 500mg Tablets and pills 
Tindazole Roxane laboratories 500mg Tablets 
 
4.2 DILOXANIDE FURATE 
Structure: 
Fig no 4.2.1 Structure of Diloxanide Furoate 
 
Chemical Name : 4-[(d ichloroacetyl)(methyl)amino]phenyl  
  furan-2-carboxylate 
Molecular Formula : C14H11ClNO4
  
Molecular Weight : 328.2 g/mol. 
Melting point        : 114-116 
PKa Value                   :   4.7 (strong basic) and 13.09 (strong acidic) 
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Drug Category : Antiprotozoal. 
Solubility : Diloxanide furoate is very slightly soluble in water,  
  soluble to the extent of 1 in 100 in alcohol, 1 in 25 of  
  chloroform, and 1 in 130 of ether. 
Description : White or almost white crystalline powder 
Storage                      : Store at room temperature between 59 and 86 degrees F  
  (15 to 30 degrees C) away from heat and light.  
Dosage Forms           :   Tablets 
Available does      : 500 mg.  
CLINICAL PHARMACOLOGY 
Mechanism of action    
 Dioxanide furoate luminal amebicide.The mechanism of action of diloxanide 
is unknown. This agent destroys the trophozoites of E. histolytica that eventually 
form into cysts. The cysts are then excreted by persons infected with asymptomatic 
amebiasis.  
Pharmacokinetic Parameters:  
Bioavailability : 90%. 
Metabolism    : hydrolyze to furoic acid and diloxanide which under goes  
   extensive glucuronidation. 
Half-life   : 3 hours. 
Excretion            : Renal (90%) fecal (10 %). 
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Contraindications:    
 Contraindicated in hypersensitivity. 
 It is contraindicated in children below 2 years. 
Drug Interactions: 
 No interactions of Diloxanide furoate with other has not been fully studied or 
established. 
SIDE EFFECTS:  
The side effects of Diloxanide Furoate include  
 Flatulence 
 Nausea 
 Vomiting 
 Anorexia 
 Diarrhea 
 Abdominal cramps 
 Urticaria 
 Esophagitis 
 Paresthesia 
 Albuminuia 
USES: 
Diloxanide is used to treat an infection caused by a parasite in your bowel. 
Infection occurs after drinking water contaminated by infected faeces, or eating food 
prepared or washed using contaminated water. People most at risk of amoebiasis 
include travellers to areas where amoebiasis is common, such as countries with poor 
sanitation. Treatment includes medication such as diloxanide to kill the parasite, and 
drinking plenty of fluids to prevent dehydration. 
Chapter 4 Durg Profile 
Dept. of Pharmaceutical Analysis 58 J.K.K. Nattraja College of Pharmacy 
BRAND NAMES: 
Brand Name Manufacturer Strength Type of 
form 
Amiciline Franco Indian pharmaceuticals 500 mg Tablet 
Furamide Abbott health care (p) ltd 500 mg Tablet 
Dilamide Pharmadesh laboratories ltd 500mg Tablet 
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5. MATERIALS AND METHODS 
The various materials and equipment’s used for the present study are 
summarized as follows. 
CHEMICALS/REAGENTS AND SOLVENTS 
S.No. Materials Grade Company 
1 Potassium dihydrogen orthophosphate AR MERCK 
2 Methanol HPLC MERCK 
3 Acetonitrile HPLC MERCK 
4 Water HPLC MERCK 
5 Ortho phosphoric acid AR MERCK 
6 Hydrochloric acid AR MERCK 
7 Sodium Hydroxide AR MERCK 
8 Hydrogen Peroxide AR MERCK 
 
Table No: 5.1 List of Various Chemicals and Solvents Used 
S.No Working standard Potency 
1 Tinidazole 99.6 % 
2 Diloxanide Furoate  99.6 % 
 
Table No. 5.2 Working Standard / Reference Standard/ API 
Brand name Composition 
METROQUIN Tinidazole  -  300 mg 
+ 
Diloxanide Furoate    -   250 mg 
 
Table No. 5.3 Test Sample 
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EQUIPMENTS: 
S.NO Name of equipment Software Model Company 
1. HPLC Empower Waters 2695 Waters 
2. UV – spectrophotometer Spectral treats SL 159 ELICO 
3. pH meter N/A LI615 ELICO 
4. Weighing balance N/A A X 200 SHIMADZU 
5. Sonicator N/A ISO 9001- 2000 PCI 
6. Vaccum filter N/A PDF2-75 PROMIVAC 
 
Table No. 5.4 List o f Various Equipments Used 
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                   6. METHOD DEVELOPMENT & VALIDATION 
6.1 METHOD DEVELOPMENT 
Instrument and Materials 
            An UV-SL 159 Series UV / Visible double beam Spectrophotometer with 1 
cm matched quartz cells was used for all spectral measurements. All chemicals used 
were of Analytical Reagent (AR) grade from, Merck, Fischer scientific and 
Qualigen. 
Solvent Selection 
In order to select suitable solvent for determination of Tinidazole and 
Diloxanide Furoate various solvents were selected for the solubility studies and it 
was found that they were freely soluble in methanol. Hence in the present work, 
methanol was used for all the dilutions. 
Preparation of Standard Stock Solution of Tinidazole  
Accurately weighed and transferred 10 mg of  Tinidazole working standard 
into a 100 ml clean dry volumetric flask  and it was dissolved by using methanol and 
the volume was made up to the mark with methanol (100 µg/ml). 
1 ml of the above standard stock solution was pipetted into 10 ml volumetric 
flasks and diluted up to the mark with methanol to get concentration of 10 µg/ml.  
Preparation of Standard Stock Solution of Diloxanide Furoate 
Accurately weighed and transferred 10 mg of Diloxanide furoate  working 
standard into a 100 ml clean dry volumetric flask  and it was dissolved by using 
methanol and volume was made up to the mark with methanol (100 µg/ml). 
1 ml of the above standard stock solution was pipetted into 10 ml volumetric 
flasks and diluted up to the mark with methanol to get concentration of 10µg/ml.  
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Optimization of UV- conditions 
 Initially method development work was done in UV by taking UV-visible 
spectra from the wavelength range of 200-400 nm for Tinidazole and Diloxanide 
furoate standard solutions. Results revealed the isobestic point of Tinidazole and 
Diloxanide furoate standard was 278 nm. The isobestic point of two drugs shows 
maximum absorbance at 278 nm. Hence this λmax of 278 nm was utilized for HPLC 
method development. 
 
Fig No 6.1 Isobestic point of Tinidazole and Diloxanide furoate. (278 nm) 
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6.2 HPLC METHOD DEVELOPMENT TRAILS 
Trail: 1 
Preparation of Phosphate buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degas to sonicate and finally make up the volume with milli –Q water and pH 
adjusted to 5.0 with dil.Orthophosphoric acid solution 
 Mobile phase: 
Buffer and Acetonitrile taken in the ratio 30:70 % v/v. 
Diluent preparation: ACN: Water (50:50 % v/v) 
 Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
Chromatographic conditions: 
Flow rate : 1.0 ml/min 
Column : Hypersil BSD C18  ( 250 x 4.6 mm, 5.particle size) 
Detector wave length : 278nm 
Column temperature :  30°C 
Injection volume : 10L 
Run time : 15 min 
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Fig no.6.2  Chromatogram of tail ( 1) 
S.No 
Sample 
name 
Retention 
time(min) 
Peak 
Area 
% 
peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 3.5 136055 40.22 1.30 4771 
22.74 
2 
Diloxanide 
furoate 
13.409 225442 56.15 1.35 6534 
 
Observation: Retention time and Resolution were found to be more. 
Trail: 2 
Preparation of buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degas to sonicate and finally make up the volume with milli –Q water and pH 
adjusted to 5.0 with dil.Orthophosphoric acid solution 
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 50:50 % v/v. 
Diluent preparation: ACN: Water (50:50 % v/v) 
 Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
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Chromatographic conditions : 
Mobile phase   : KH2PO4: Acetonitrile (50:50 ml) 
Flow rate                 : 1.0 ml/min 
Column                         : Hypersil BDS C18 (250 x 4.6 mm, 5.) 
Detector wavelength : 278 nm 
Injection volume : 10 µl 
Run time                : 15 min 
Temperature      : 300C 
 
Fig no 6.3 Chromatogram of tail (2) 
S.No 
Sample 
name 
Retention 
time(min) 
Peak 
Area 
% 
peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 3.488 121946 37.75 0.79 2820 
12.90 
2 
Diloxanide 
furoate 
6.482 201090 62.25 1.17 17324 
 
Observation: Resolution was found to be more. 
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Trail: 3 
Preparaion of buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degassed. Finally make up the volume with water the added 1ml of triethylamine 
and then  pH adjusted to 3.3 with dil.Orthophosphoric acid solution 
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 40:60 % v/v. 
Diluent preparation: ACN: Water (50:50 % v/v) 
 Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
Chromatographic conditions: 
Mobile phase   : KH2PO4: Acetonitrile (40:60 V/V) 
Flow rate                 : 1.1 ml/min 
Column                   : Hypersil BDS C18 (250 x4.6 mm 5 µ particle size) 
Detector wavelength : 278 nm 
Injection volume    : 10 µl 
Run time                 : 6 min 
Temperature    : 300C 
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Fig no 6.4 Chromatogram of tail  (3) 
S.No 
Sample 
name 
Retention 
time(min) 
Peak 
Area 
% 
peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 2.627 144621 42.61 1.14 3416 
 
10.02 2 
Diloxanide 
furoate 
4.985 183418 55.39 0.77 5798 
 
Observation: Retention time was found to be more. 
Trail: 4  
Preparaion of buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degassed. Finally make up the volume with water the added 1ml of triethylamine 
and then  pH adjusted to 5.0 with dil.Orthophosphoric acid solution 
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 60:40 % v/v. 
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Diluent preparation: ACN: Water (50:50 % v/v) 
 Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
Chromatographic conditions: 
Mobile phase    : KH2PO4: Acetonitrile (60:40 ml) 
Flow rate                 : 1.0 ml/min 
Column                     : Hypersil BSD C18 (250 x4.6 mm, 5 µ particle size). 
Detector wavelength : 278 nm 
Injection volume    : 10 µl 
Run time                    : 15 min 
Temperature            : 300C  
Fig No 6.5 Chromatogram for trail (4) 
S.No 
Sample 
name 
Retention 
time(min) 
Peak  
Area 
% 
peak  
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 2.079 166758 41.99 1.26 3323 
17.66 
2 
Diloxanide 
furoate 
7.067 230392 58.01 1.05 4767 
 
Observation: Retention time was found to be more. 
Chapter 6 Method Devleopment and Validation 
Dept. of Pharmaceutical Analysis 69 J.K.K. Nattraja College of Pharmacy 
Trail: 5 
Preparaion of buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degassed. Finally make up the volume with water the added 1ml of triethylamine 
and then  pH adjusted to 3.3 with dil.Orthophosphoric acid solution 
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 55:45 % v/v. 
Diluent preparation: ACN: Water (50:50 % v/v) 
Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
Chromatographic conditions: 
Mobile phase : KH2PO4: Acetonitrile (55:45 ml) 
Flow rate                        : 1.0 ml/min 
Column                          : Hypersil OSD C18 (250 x4.6 mm, 5 µ particle size.) 
Detector wavelength : 278 nm 
Injection volume    : 10 µl 
Run time                      : 10 min 
Temperature               : 300C 
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fig No 6.6 Chromatogram for trail (5) 
S. 
No. 
Sample 
name 
Retention 
time(min) 
Peak 
Area 
% 
peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 2.306 427856 42.23 1.35 5468 
10.41 
2 
Diloxanide 
furoate 
3.952 566834 54.65 1.21 7437 
 
Observation: Retention time and resolution were found to be more. 
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OPTIMIZED METHOD 
Preparaion of buffer: 
Transferred an accurately weighed 1.36gm of Potassium di-hydrogen Ortho 
phosphate into a 1000 ml volumetric flask, 900 ml of milli-Q water was added and 
degassed. Finally make up the volume with water the added 1ml of triethylamine 
and then  pH adjusted to 3.3 with dil.Orthophosphoric acid solution 
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 45:55% v/v. 
Diluent preparation: ACN: Water (50:50 % v/v) 
 Accurately 50 ml of acetonitrile and 50 ml of milli-Q water were measured 
and mixed well. 
Chromatographic conditions: 
Mobile phase : Phosphate Buffer ( KH2PO4 ) : Acetoitrile  (45:55V/V) 
Flow rate                    : 1.0 ml/min 
Column                      : Hypersil OSD C18 (250 x 4.6 mm, 5 µ particle size). 
Detector wavelength : 278 nm 
Injection volume     : 10 µl 
Run time                   : 10 min 
Temperature               : 300C 
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Fig No 6.7 Chromatogram for optimized method 
S. 
No. 
Sample 
name 
Retention 
time(min) 
Peak 
Area 
%peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution 
1 Tinidazole 2.443 464001 43.40 1.32 5630 
7.89 
2 
Diloxanide 
furoate 
3.653 605076 56.60 1.24 7362 
 
Observation: Retention time was less and Peak shapes were good 
6.8 METHOD VALIDATION 
Method validation was performed as per the ICH guidelines. The developed 
method was validated for the following parameters. 
1. System  Suitability 
2. Specificity 
3. Linearity and Range 
4. Accuracy 
5. Precision 
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6. LOD & LOQ 
7. Robustness 
8. Ruggedness 
1) SYSTEM SUITABILITY: 
 System suitability test should be carried out to verify that the analytical 
system is working properly and can give accurate and precise results. Standard 
solutions were prepared as per the test method and injected into the chromatographic 
system. The system suitability parameters were evaluated from tailing factor, 
retention times and theoretical plates of standard chromatograms. 
Procedure: 
Standard solution preparations were injected into the chromatograph and 
system suitability parameters   were recorded.  The results obtained are tabulated in 
table no.7.9  
2) SPECIFICITY: 
Specificity is the ability to assess unequivocally the analyte in the presence 
of compounds that may be expected to present, such as impurities, degradation 
products and matrix components. The specificity of the method was assessed by 
comparing the chromatograms obtained from the drug standards with that of 
obtained from the tablet solution .The retention times of the drug standards and the 
drug from sample solutions were found to be same. The method was also specific 
and selective because there was no interference from excipients in the Tablets. 
3) LINEARITY: 
The linearity of an analytical method was carried out to check its ability to 
elicit test results that are directly, or by a well-defined mathematical transformation, 
proportional to the concentration of analyte in samples within a given range. 
Different levels of standard solutions were prepared and injected into the HPLC 
and the chromatograms were recorded.  
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Procedure: 
Preparation of Standard Stock Solution: (12000µg/ml of Tinidazole and 
1000µg/ml of Diloxanide Furoate) 
Accurately weighed and transferred 12mg of Tinidazole and 10mg of 
Diloxanide working Standards into a 10 ml clean dry volumetric flask, add 7ml of 
diluent, sonicated for 5 minutes and make up to the final volume with diluents. 
Preparation of working standard solution: (120µg/ml of Tinidazole and 
100µg/ml of Diloxanide Furoate) 
From the above two stock solutions,1ml  was Pipetted out  into a 10ml 
volumetric flask and made up to final volume with diluent. 
Preparation of Sample Solution: (120µg/ml of Tinidazole and 100µg/ml of 
Diloxanide Furoate) 
20 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 120 mg of Tinidazole and 100 mg Diloxanide Furoate 
transferred into a 100mL volumetric flask, 70mL of diluent added and sonicated for 
25 min, further the volume made up with diluent and filtered. From the filtered 
solution 1 ml was Pipetted out into a 10 ml volumetric flask and made up to 10ml 
with diluent. 
Procedure: Standard and sample solutions were injected into the 
chromatogram and results obtained are shown in table no 7.17 
Preparation of serial dilutions  
Different  levels  of  standard  solution  were  prepared  by  pipetting  out  
known  volume of stock solution and made up to volumes with the diluent to get 
different analyte concentrations. Injected above solutions into the chromatograph 
(Injected higher levels five times for precision).  Recorded the area response for 
each level and calculated the slope, intercept, correlation coefficient and regression 
coefficient (R square). Test the intercept for statistical equivalence to zero. A graph 
of concentration (ppm) on X-axis and area on Y axis was plotted.  
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Table no. 6.3 Preparation of standard serial  dilutions for linearity of 
Tinidazole  and Diloxanide Furoate: 
S.No 
Pipetted 
from stock  
(ml) 
Volume of 
flask (ml) 
Concentration 
in ppm(Tinid) 
Concentration 
in ppm(Dilo) 
%Linearity 
Level 
1 0.25 10 30 25 25 
2 0.5 10 60 50 50 
3 0.75 10 90 75 75 
4 1 10 120 100 100 
5 0.25 10 150 125 125 
6 0.50 10 180 150 150 
 
4) ACCURACY: 
The accuracy of an analytical method is the closeness of agreement between 
the value which is accepted either as a conventional true value or an accepted 
reference value and the value found.  
The study was performed by making three different standard concentrations 
at 50%,100% and 150% levels of known amounts of studied drugs.  The accuracy 
of an analytical method should be established across its range. Finally, the final 
volume made up with diluent (ACN: Water 50:50 % v/v) and mixed well. The 
resulting mixtures were analyzed by the proposed HPLC method at 278 nm.  
Preparation of Standard Stock Solution: (12000µg/ml of Tinidazole and 
1000µg/ml of Diloxanide Furoate) 
Accurately weighed and transferred 12mg of Tinidazole and 10mg of 
Diloxanide working Standards into a 10 ml clean dry volumetric flask, add 7ml of 
diluent , sonicated for 5 minutes and make up to the final volume with diluents. 
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Preparation of working standard solution: (120µg/ml of Tinidazole and 
100µg/ml of Diloxanide Furoate) 
From the above two stock solutions,1ml  was Pipetted out  into a 10ml 
volumetric flask and made up to final volume with diluent. 
Preparation of Sample Solution: (120µg/ml of Tinidazole and 100µg/ml of 
Diloxanide Furoate) 
20 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 120 mg of Tinidazole and 100 mg Diloxanide Furoate 
transferred into a 100mL volumetric flask, 70mL of diluent added and sonicated for 
25 min, further the volume made up with diluent and filtered. From the filtered 
solution 1 ml was Pipetted out into a 10 ml volumetric flask and made up to 10ml 
with diluent.  
Preparation of 50 % Standard Addition Sample 
To 0.5 ml of sample stock solution present in 10 ml volumetric flask, 0.25 ml 
of standard stock solution was added and diluted up to the mark with the mobile 
phase. 
Preparation of 100 % Standard Addition Sample 
To 0.5 ml of sample stock solution present in 10 ml volumetric flask, 0.5 ml 
of standard stock solution was added and diluted up to the mark with the mobile 
phase. 
Preparation of 150 % Standard Addition Sample 
To 0.5 ml of sample stock solution present in 10 ml volumetric flask, 0.75 ml 
of standard stock solution was added and diluted up to the mark with the mobile 
phase. 
Acceptance criteria: 
The % of recovery should be between 98 to 102%. 
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5) PRECISION: 
 The precision of an analytical method is the degree of agreement among 
individual test results when the method is applied repeatedly to multiple sampling of 
homogeneous sample. The precision of analytical method is usually expressed as the 
standard deviation or relative standard deviation (coefficient of variation) of series 
of measurements.  
% 𝑅𝑆𝐷 =
standard deviation 
mean
 × 100 
a) System Precision: 
  The system precision was carried out to ensure that the analytical system is 
working properly by Injecting standard preparation six times into the HPLC and 
calculated the %RSD for Tiniazole and Diloxanide furoate. The results obtained are 
tabulated in table no. 8.6 The retention time and area of six determinations are  
measured and % RSD were  calculated. 
Preparation of Standard Stock Solution: (12000µg/ml of Tinidazole and 
1000µg/ml of Diloxanide Furoate) 
Accurately weighed and transferred 12mg of Tinidazole and 10mg of 
Diloxanide working Standards into a 10 ml clean dry volumetric flask, add 7ml of 
diluent , sonicated for 5 minutes and make up to the final volume with diluents. 
Preparation of working standard solution: (120µg/ml of Tinidazole and 
100µg/ml of Diloxanide Furoate) 
From the above two stock solutions,1ml  was Pipetted out  into a 10ml 
volumetric flask and made up to final volume with diluent. 
Acceptance criteria: 
The % RSD for the area of six standard injections results should not be more 
than 2 % as shown in the table no. 8.6. 
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b) Method Precision: 
In  method  precision,  a  homogenous  sample  of  a  single  batch  should be 
analyzed six  times and was checked whether the method is giving consistent 
results for a single batch. The samples of Tinidazole and Diloxanide furoate were 
analyzed six times. The % RSD was calculated for the sample.  
Preparation of Sample Solution: (120µg/ml of Tinidazole and 100µg/ml of 
Diloxanide Furoate) 
20 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 120 mg of Tinidazole and 100 mg Diloxanide Furoate 
transferred into a 100mL volumetric flask, 70mL of diluent added and sonicated for 
25 min, further the volume made up with diluent and filtered. From the filtered 
solution 1 ml was Pipetted out into a 10 ml volumetric flask and made up to 10ml 
with diluent.  
Acceptance criteria 
The % RSD for the area of six sample injections results should not be more 
than 2 % as shown in table no.8.7. 
6) Detection Limit and Quantitation Limit (LOD and LOQ): 
The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily quantitated 
as an exact value and the quantitation limit of an individual analytical procedure is 
the lowest amount of analyte in a sample which can be quantitatively determined 
with suitable precision and accuracy .The detection limit and the quantitation limit 
can be calculated based on the Standard Deviation of the Response and the Slope. . 
  Limit of Detection (LOD):  
            The parameter LOD was determined on the basis of response and slope of 
the regression equation.  
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The Detection Limit (DL) may be expressed as:  
DL = 3.3 F/S   
      Where,  
      F = Residual Standard deviation of the response,  
S = Slope of the calibration curve. 
The LOD for this method was found to be   0.25  µg/ml and 0.20   µg/ml for 
Tinidazole and Diloxnide Furoate respectively. 
Limit of Quantification (LOQ): 
The parameter LOQ was determined on the basis of response and slope of 
the regression equation. 
The Quantitation Limit (QL) may be expressed as:  
QL = 10 F/S  
Where,  
F = Residual Standard deviation of the response,  
S = Slope of the calibration curve. 
The LOQ for this method was found to be 0.76 µg/ml and 0.59 µg/ml for 
Tinidazole and Diloxanide furoate respectively. 
7) ROBUSTNESS: 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
The robustness of the proposed method was determined by analysis of 
aliquots from homogenous lots by differing physical parameters like mobile phase 
composition, flow rate and temperature which may differ but the responses were still 
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within the specified limits of the assay. The standard solution, sample solution and 
sample solution spiked with impurities were injected into the chromatograph at 
varied conditions of flow rate ± 0.1%ml/min,  mobile phase  composition by ± 10% 
organic phase buffer pH ± 0.2 units and temperature by ± 5o c  
a) Effect of variation of flow rate 
A study was conducted to determine the effect of variation in flow rate. 
Standard solution was prepared and injected into the HPLC system by keeping 
variation in flow rate + or – 10% (0.1 ml/min). The effect of variation of flow rate 
was evaluated.  
b) Effect of variation of Temperature 
A study was conducted to determine the effect of variation in temperature. 
Standard solution was prepared and injected into the HPLC system by keeping 
variation in temperature + or – 50c. The effect of variation of temperature was 
evaluated. 
ASSAY OF FORMULATION 
Preparation of Standard Stock Solution: (12000µg/ml of Tinidazole and 
1000µg/ml of Diloxanide Furoate) 
Accurately weighed and transferred 12mg of Tinidazole and 10mg of 
Diloxanide working Standards into a 10 ml clean dry volumetric flask, add 7ml of 
diluent , sonicated for 5 minutes and make up to the final volume with diluents. 
Preparation of working standard solution: (120µg/ml of Tinidazole and 
100µg/ml of Diloxanide Furoate) 
From the above two stock solutions,1ml  was Pipetted out  into a 10ml 
volumetric flask and made up to final volume with diluent. 
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Preparation of Sample Solution: (120µg/ml of Tinidazole and 100µg/ml of 
Diloxanide Furoate) 
20 tablets were weighed and calculate the average weight of each tablet then 
the weight equivalent to 120 mg of Tinidazole and 100 mg Diloxanide Furoate 
transferred into a 100mL volumetric flask, 70mL of diluent added and sonicated for 
25 min, further the volume made up with diluent and filtered. From the filtered 
solution 1 ml was Pipetted out into a 10 ml volumetric flask and made up to 10ml 
with diluent. 
Inject 10µl of filtered portion of the sample and standard  into the 
chromatograph. Record the responses for the major peaks. Calculate the amount of 
Tinidazole and Diloxanide Furoate per each tablet from the following expression. 
Calculation:    
                                                                    Spl area x Stddil  x potency 
Amount present in each tablet     = ----------------------------------------  x Avg Wt 
                                                                              Stdarea x Spl dil  
                                                                       Amount present (mg) 
                              % Assay    = ----------------------------------------  x 100 
                                                                             Label claim 
Where, 
            Avg wt = average weight of tablets. 
            Spl area   = Sample area 
            Std area  =Standard area 
            Stddil     =Standard dilution 
            Spl dil     =Sample dilution 
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Assay of Tinidazole: 
               Assay %      = ---------------------------------------- x100 
Assay of Diloxanide Furoate  : 
               Assay %      = ---------------------------------------- x100 
Acceptance criteria 
The percentage purity of Tinidazole and Diloxanide Furoate should be not 
less than 90% and not more than 110%. 
DEGRADATION STUDIES: 
Acid Degradation Studies:  
To 1 . 0  ml of working  solut ion of Tinidazole and Diloxanide, 1 ml of 2N 
Hydrochloric acid was added and refluxed for 30mins at 600c .The resultant 
solution was diluted to obtain 120µg/ml&100µg/ml solution and 10 µl 
solutions were injected into the system and the chromatograms were recorded to 
assess the stability of sample. 
Alkali Degradation Studies: 
To 1.0 ml of working solution of Tinidazole and Diloxanide, 1 ml of 2N 
sodium hydroxide was added and refluxed for 30mins at 600c. The resultant 
solution was diluted to obtain 120µg/ml&100µg/ml solution and 10 µl were 
injected into the system and the chromatograms were recorded to assess the 
stability of sample. 
Oxidation: 
To 1.0 ml of working solution of Tinidazole and Diloxanide, 1 ml of 20% 
hydrogen peroxide (H2O2) was added separately. The solutions were kept for 30 
min at 600c. For HPLC study, the resultant solution was diluted to obtain 
120µg/ml&100µg/ml solution and 10 µl were injected into the system and the 
chromatograms were recorded to assess the stability of sample. 
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Dry Heat Degradation Studies: 
The standard drug solution was  placed in oven at 1050c for 6 h to study 
dry heat degradation. For HPLC study, the resultant solution was diluted to 
120µg/ml&100µg/ml solution and10µl were injected into the system and the 
chromatograms were recorded to assess the stability of the sample. 
Photo Stability studies: 
The photochemical stability of the drug was also studied by exposing the 
solution to UV Light by keeping the beaker in UV Chamber for 7days or 200 Watt 
hours/m2 in photo stability chamber. For HPLC study, the resultant solution was 
diluted to obtain 120µg/ml&100µg/ml solutions and 10 µl were injected into the 
system and the chromatograms were recorded to assess the stability of sample. 
Neutral Degradation Studies: 
The photochemical stability of the drug was also studied by exposing the 
solution to UV Light by keeping the beaker in UV Chamber for 7days or 200 Watt 
hours/m2 in photo stability chamber. For HPLC study, the resultant solution was 
diluted to obtain 120µg/ml&100µg/ml solutions and 10 µl were injected into the 
system and the chromatograms were recorded to assess the stability of sample. 
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7. RESULTS AND DISCUSSION 
7.1 SYSTEM SUITABILITY: 
Fig:1 Chromatogram of System suitability Standard Solution 
 
Table No.7.1 System Suitability: 
S.No Sample 
name 
Retention 
time(min) 
Peak 
Area 
% 
peak 
Area 
USP 
Tailing 
USP 
Plate 
Count 
Resolution  
1 Tinidazole 2.443 464001 43.40 1.32 5630 7.89 
2 Diloxanide 
furoate  
3.653 605076 56.60 1.24 7362 
 
Data interpretation: 
It is observed from the tabulated above, that system suitability parameters are 
within the acceptable limit. Hence it can be concluded that the system suitability 
parameters met the requirements of method validation. 
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7.2 SPECIFICITY: 
Fig: 2 Chromatogram of Blank solution : 
 
Fig: 3 Chromatogram of Standards solution: 
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Fig: 4 Chromatogram of Sample  
solution:
 
Table No. 7.2 Specificity Results  
S.No Compound name 
Retention time 
Tinidazole Diloxanide furoate 
1 Blank - - 
2 Standard 2.438 3.640 
3 Sample 2.441 3.644 
 
Data interpretation 
1. The selectivity of the method was checked by injecting solutions of both 
Tinidazole and Diloxanide Furoate . It was observed that two sharp peaks for 
each drug were obtained at retention times of 2.441 and 3.644 min respectively. 
The found Rt of test and standard peaks was almost equal and diluents did not 
interfered with the peaks.  
2. The retention times of drug standards and drug samples were almost same. 
Hence the method was specific. 
3. The method was also found to be specific & selective because there was no 
interference from excipients in the tablets. 
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7.3 LINEARITY:  
Fig: 5 Chromatogram of Linearity 25% : 
 
Fig: 6 Chromatogram of Linearity 50 % : 
 
Fig: 7 Chromatogram of Linearity 75 % : 
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Fig: 8 Chromatogram of linearity 100% : 
 
Fig: 9 Chromatogram of Linearity of 125 %: 
 
Fig: 10 Chromatogram of Linearity of 150 % : 
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Table No.7.3 Linearity studies of Tinidazole 
S.NO Concentration (µg/ml) Peak Area 
1 30 115108 
2 60 235766 
3 90 355006 
4 120 474538 
5 150 600806 
6 180 697209 
Correlation coefficient(r2) 0.999 
Slope (m) 3930 
Intercept 298.1 
 
Fig. No 7.1 Linearity Graph for Tinidazole 
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Table.no- 7.4 Linearity of Diloxnide Furoate 
S.NO Concentration  (µg/ml) Peak Area 
1 25 149734 
2 50 305874 
3 75 452938 
4 100 598634 
5 125 770138 
6 150 899711 
Correlation coefficient(r2) 0.999 
Slope (m) 6046 
Intercept 357.6 
 
Fig. No.7.2 Linearity studies  for Diloxanide Furoate 
 
Data interpretation: 
The correlation coefficient (or) regression coefficient should not be less than 
0.999. Calculate the correlation coefficient (r2), y-intercept and slope. From the 
statistical treatment of linearity data of Tinidazole and Diloxanide Furoate it was 
clear that the response is linear between lower levels to higher levels. The 
correlation coefficient was found to be 0.999. 
y = 6046.7x + 357.61
R² = 0.9995
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7.4 ACCURACY: 
Fig: 11 Chromatogram of Sample 50% (1): 
Fig:12 Chromatogram of Sample 50%(2): 
 
Fig: 13 Chromatogram of Sample 50% (3): 
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Fig: 14 Chromatogram of Sample 100% (1): 
 
Fig: 15 Chromatogram of Sample 100% (2): 
 
Fig: 16 Chromatogram of Sample 100%(3): 
 
Chapter 7 Results and Discussion 
Dept. of Pharmaceutical Analysis 93 J.K.K. Nattraja College of Pharmacy 
Fig: 17 Chromatogram of Sample 150%(1): 
 
Fig: 18 Chromatogram of Sample 150% (2): 
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Fig: 19 Chromatogram of Sample 150% (3): 
 
 
 
Table No 7.5 Acuuracy for Tinidazole and Diloxanide Furoate 
Sample Accuracy Peak Area %  Recovery Mean %  
Recovery 
Overall Mean 
%Recovery 
 
Tinidazole 
 
 
 
 
50% 225551 99.75 MEAN=99.85 
S.D   = 0.22 
%RSD = 0.22 
 
MEAN= 99.89 
S.D     = 0.165 
%RSD = 0.165 
50% 226374 100.11 
50% 225424 99.69 
100% 454713 100.55 MEAN=100.08 
S.D    = 0.40 
%RSD = 0.39 
100% 451882 99.92 
100% 451282 99.79 
150% 674477 99.43 MEAN=99.76 
S.D   = 0.30 
%RSD = 0.30 
150% 677286 99.84 
150% 678582 100.03 
 
Diloxanide 
Furoate 
50% 300874 100.66 MEAN=100.21 
S.D    = 0.66 
%RSD = 0.65 
 
MEAN= 100.11 
S.D    = 0.095 
%RSD = 0.09 
50% 297250 99.45 
50% 300525 100.54 
100% 593292 99.24 MEAN = 100.02 
S.D    = 0.67 
%RSD  = 0.66 
100% 600461 100.44 
100% 600065 100.38 
150% 899800 100.34 MEAN=100.12 
S.D   = 0.34 
%RSD = 0.33 
150% 899510 100.31 
150% 894341 99.73 
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Data interpretation 
 The Mean % Recovery at 50%,100% and 150% at higher  levels for 
Tinidazole and Diloxanide Furoate were found  to be between  99.89 % and  
100.11%  which were  within the  acceptance criteria limit. 
 The Mean % Recovery for Tinidazole at 50%,100% and 150%  levels was 
found to be 99.85%, 100.08% and 99.76% respectively and are within the limits. 
 The Mean % Recovery for Diloxanide furoate at 50%,100% and 150% 
levels was found to be 100.21%, 100.02% and 100.12% respectively and are within 
the limits. 
 The excellent mean recoveries and standard deviation suggested that the 
good accuracy of the proposed method. 
7.6 PRECISION: 
i) System Precision: 
Fig: 20 Chromatogram of System Precision (1): 
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Fig: 21 Chromatogram of System Precision (2): 
 
Fig: 22 Chromatogram of System Precision (3): 
 
Fig: 23 Chromatogram of System Precision (4): 
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Fig: 24 Chromatogram of System Precision (5): 
 
Fig: 25 Chromatogram of System Precision (6): 
 
Table No.7.7 System Precision of Tinidazole and Diloxanide furoate: 
 Tinidazole Diloxanide Furoate 
S No RT Area RT Area 
1 2.438 453961 3.640 593318 
2 2.439 450640 3.640 600062 
3 2.440 455090 3.642 594119 
4 2.440 450337 3.642 599686 
5 2.441 444217 3.642 592891 
 2.441 448218 3.644 592273 
Avg  450441  595392 
Std Dev  3942.8  3526 
RSD  0.9  0.6 
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Data interpretation: 
The retention time and area for Tinidazole and Diloxanide furoate peaks 
obtained from six replicate injections are consistent as evidenced by the values of 
relative standard deviation. Hence it can be concluded that the system precision 
parameter meets the requirement of method validation. 
ii) Method Precision: 
Fig: 26 Chromatogram of Method Precision (1): 
 
Fig: 27 Chromatogram of Method Precision (2): 
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Fig: 28 Chromatogram of Method Precision (3): 
 
 
Fig: 29 Chromatogram of Method Precision (4): 
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Fig: 30 Chromatogram of Method Precision (5): 
 
 
Fig: 31 Chromatogram of Method Precision 6: 
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Table No.7.8 Method Precision of Tinidazole and Diloanide Furoate : 
 Tinidazole DiloxanideFuroate 
S No RT Area RT Area 
1 2.439 447916 3.642 594845 
2 2.441 448928 3.644 595903 
3 2.453 454769 3.688 601566 
4 2.459 448153 3.719 591800 
5 2.463 450212 3.727 592833 
6 2.463 452618 3.733 598582 
Avg  450433  595922 
Std Dev  2736  3650 
% RSD  0.6  0.6 
 
Data interpretation: 
Test results Tinidazole and Diloxanide Furoate  were shown that the % RSD 
of peak areas and retention times are within limits. Hence it can be concluded that 
the method is precise. 
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7.9 Intermediate Precision: 
Intermediate Precision Day - 1: 
Fig: 32 Chromatogram Intermediate Precision Day - 1: (1) 
 
Fig: 33 Chromatogram Intermediate Precision Day - 1: (2) 
 
Fig: 34 Chromatogram Intermediate Precision Day - 1: (3) 
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Fig: 35 Chromatogram Intermediate Precision Day - 1: (4) 
 
Fig: 36 Chromatogram Intermediate Precision Day - 1:( 5) 
 
Fig: 37 Chromatogram Intermediate Precision Day - 1: (6) 
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Table No 7.10 Intermediate Precision Day – 1 : 
S No Tinidazole Diloxanide Furoate 
  RT Area RT Area 
1 2.438 448247 3.640 592102 
2 2.439 447916 3.640 593877 
3 2.439 442242 3.642 593144 
4 2.440 444679 3.642 593671 
5 2.441 444217 3.642 586570 
 
2.441 442305 3.644 587384 
Avg 
 
444934 
 
591125 
Std Dev 
 
2631.0 
 
3281.3 
% RSD 
 
0.6 
 
0.6 
  
 
   
Chromatogram of Intermediate Precision Day – 2: 
Fig: 38 Chromatogram of Intermediate Precision Day – 2 (1) 
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Fig: 39 Chromatogram of Intermediate Precision Day – 2 (2) 
 
Fig: 40 Chromatogram of Intermediate Precision Day – 2 (3) 
 
Fig: 41 Chromatogram of Intermediate Precision Day – 2 (4) 
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Fig: 42 Chromatogram of Intermediate Precision Day – 2 (5) 
 
Fig: 43 Chromatogram of Intermediate Precision Day – 2 (6) 
 
Chapter 7 Results and Discussion 
Dept. of Pharmaceutical Analysis 107 J.K.K. Nattraja College of Pharmacy 
Table No 7.11 Intermediate Precision Day – 2 : 
S No Tinidazole Diloxanide Furoate 
  RT Area RT Area 
1 2.438 448247 3.640 592102 
2 2.439 442242 3.640 593877 
3 2.440 449008 3.642 589066 
4 2.440 444679 3.642 592811 
5 2.441 444217 3.642 586570 
 
2.441 442305 3.644 587384 
Avg 
 
445116 
 
590302 
Std Dev 
 
2902.1 
 
3042.6 
% RSD 
 
0.7 
 
0.5 
 
7.12 LIMIT OF DETECTION: 
Fig 44 Chromatogram of Standard: 
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7.13 LIMIT OF QUANTIFICATION: 
Fig 45 Chromatogram of Standard: 
 
Tinidazole: 
LOD = 3.3 F/S 
        = 3.3 ×298.1/3930 = 0.25 
LOQ = 10 F/S 
          =10 × 298.1/3930 = 0.76 
Diloxanide Furoate: 
LOD = 3.3 F/S 
        = 3.3 ×357.6/6046 = 0.20 
LOQ = 10 F/S 
          =10 × 357.6/6046 = 0.59 
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7.14  ROBUSTNESS: 
Fig 46 Chromatogram of Flow 1 (0.9 ml/min ): 
 
Fig 47 Chromatogram of Flow 2 (1.1 ml/min ): 
 
Fig 48 Chromatogram of Temp 1 (250c):                   
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Fig 49 Chromatogram of Temp 2 (35c c): 
 
Fig 50 Chromatogram of mobile phase 1 (50:50 % V/V): 
 
Fig 51 Chromatogram of mobile phase 2 (40:60 % V/V): 
 
Chapter 7 Results and Discussion 
Dept. of Pharmaceutical Analysis 111 J.K.K. Nattraja College of Pharmacy 
Table. No 7.15 Robustness of Tinidazole and Diloxanide Furoate : 
 Tinidazole Diloxanide Furoate 
S No Parameter RT Area 
Tailing 
factor 
RT Area 
Tailing 
factor 
1 Standard       
2 Robustness-Flow-1 2.444 445197 1.25 3.666 586483 1.16 
3 Robustness-Flow-2 2.207 434640 1.28 3.309 533051 1.15 
4 
Robustness- change 
in mobile phase_1 
2.422 466627 1.33 3.541 581740 1.19 
5 
Robustness-change 
in mobile phase_2 
2.445 449894 1.28 3.666 592388 1.18 
6 
Robustness-change 
in temp _1 
2.424 466627 1.33 3.541 581740 1.19 
7 
Robustness-change 
in temp _ 2 
2.208 434640 1.28 3.314 533051 1.16 
 
Data interpretation: 
 It was found that the system suitability parameters were within the limits at 
all variable conditions. From the results obtained it can be concluded that, this 
method is robust towards small variations in method parameters. 
7.16 CHROMATOGRAMS OF ASSAY: 
Fig 52 Chromatogram of standard 1: 
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Fig 53 Chromatogram of standard 2: 
 
Fig 54 Chromatogram of sample 1: 
 
Fig 55 Chromatogram of sample 2: 
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Table 7.17 Assay of standard & sample chromatogram   
  
TINIDAZOLE DILOXANNIDE FUROATE 
S No 
 
RT Area RT Area 
1 Standard-1 2.439 450640 3.640 600062 
2 Standard-2 2.440 455090 3.642 592891 
 
Average 
 
452865 
 
596476.5 
1 Assay-Sample 2.439 447916 3.642 595854 
2 Assay-Sample 2.441 448928 3.644 595903 
 
Average 
 
448422 
 
595878.5 
 
Calculation:                                  
 Spl area x Std dil  x potency  x Avg Wt                    
% Assay    = ------------------------------------------------------------------  x 100 
           Std area x Spl dil x weight taken x Label claim 
Where,  
Avg wt = average weight of tablets.             
Spl area = Sample area 
 Std area  = Standard area 
 Std dil      = Standard dilution 
Spl dil      = Sample dilution 
Assay of  Tinidazole 
         448422 x 12 x 1 x 100 x 10 x 99.6 x 315 
Assay %  = -------------------------------------------------------- x100 
           45286.5x 10 x 10 x124.68 x 1 x 100 x 300 
        = 99.64% 
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Assay of Diloxanide furoate : 
      595878.5x 10 x1 x100 x10 x 99.6 x 315 
Assay % = -------------------------------------------------------------- x 100 
        596476.5 x 10 x10 x 124.68 x 1 x 100 x 250 
= 100.45% 
Data interpretation 
The percentage purity of Tinidazole and Diloxanide furoate was found to be 
99.64 % and 100.45 % were within limit. From the results obtained it can be 
concluded that, this method is applied for routine analysis of simultaneous 
estimation of tinidazole and Diloxanide Furoate in their combined tablet dosage 
form. 
7.18 DEGRADATION STUDIES 
Fig 56 Chromatogram of Standard: 
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Fig 57 Chromatogram of Acid Hydrolysis: 
 
Fig 58 Chromatogram of Base Hydrolysis: 
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Fig 59 Chromatogram of Oxidation (Peroxide): 
 
Fig 60 Chromatogram of Heat Exposure: 
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Fig 61 Chromatogram of UV Exposure: 
 
Fig 62 Chromatogram of neutral hydrolysis: 
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Table. No 7.19 Degradation study of Tinidazole 
S.No Name Peak 
Area 
Degradation 
Assay 
% Net 
Degradation 
1 Acid Hydrolysis 415006 92.90 6.74 
2 Base Hydrolysis 418710 93.72 5.92 
3 Heat Exposure 425486 95.24 4.40 
4 Oxidation 
(peroxide) 
421280 94.30 5.34 
5 UV Exposure 438180 98.08 1.56 
6 Neutral 443619 99.30 0.34 
 
Table No.7.20  Degradation study of Diloxanide Furoate 
S.No Name Peak 
Area 
Degradation 
Assay 
% Net 
Degradation 
1 Acid Hydrolysis 5467557 92.12 8.33 
2 Base Hydrolysis 556333 93.73 6.72 
3 Heat Exposure 567746 95.66 4.79 
4 Oxidation 
(peroxide) 
561104 94.54 5.91 
5 UV Exposure 585874 98.71 1.74 
6 Neutral 588589 99.17 1.28 
  
 
 
Chapter 8 Summary and Conclusion 
Dept. of Pharmaceutical Analysis 119 J.K.K. Nattraja College of Pharmacy 
8. SUMMARY AND CONCLUSION 
Table No 8.1 Chromatographic Conditions 
 
System suitability parameters RESULTS 
 TINIDAZOLE 
DILOXANIDE 
FUROATE 
Retention time 2.438 3.653 
Area 464001 605076 
Theoretical plates 5630 73622 
Tailing factor 1.32 1.24 
 
Table No 8.2 System Suitability Parameters Of Assay 
Mobile phase 
Potassium dihydrogen phosphate and 
Acetonitrile(45:55 V/V) 
Stationary phase Kromasil C18 (150 x 4.6 mm, 5µ) 
Wave length 278 nm 
Run time 20 min 
P.H of mobile phase 3.3 
Flow rate 1 ml/min 
Injection volume 10µl 
Temperature 300 c 
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Table No 8.3 Validation Parameters of Assay 
 
Table No 8.4 Degradation study results: 
S. 
No 
Compound 
Name 
Acid 
hydrolysis 
Alkali 
hydrolysis 
Oxidation Heat UV Neutral 
hydrolysis 
1 Tinidazole 6.74 5.92 5.34 4.40 1.56 0.34 
2 Diloxanide 
Furoate 
8.33 6.72 5.91 4.79 1.74 1.28 
 
 
S.No 
 
Parameter 
RESULT 
Tinidazole Diloxanide Furoate 
1 Linearity 
30-180  µg/ml 
Correlation coefficient = 
0.999 
25-150 µg/ml 
Correlation coefficient  = 0.999 
2 
System precision  
%RSD 
0.9 0.6 
3 
Method precision  
%RSD 
0.6 0.6 
4 
Intermediate  
precision %RSD 
0.6 0.6 
5 
Accuracy Mean recovery = Mean recovery = 
50% 99.85% 100.21% 
100% 100.08% 100.02% 
150% 9.76% 100.12% 
6 
Robustness RT Area 
Tailing 
factor 
RT Area 
Tailing 
factor 
Flow-1 2.444 445197 1.25 3.666 586483 1.16 
Flow-2 2.207 434640 1.28 3.309 533051 1.15 
change in  
mobile phase_1 
2.422 466627 1.33 3.541 581740 1.19 
change in  
mobile phase_2 
2.445 449894 1.28 3.666 592388 1.18 
change in temp _1 2.422 466627 1.33 3.541 581740 1.19 
change in temp _ 2 2.208 434640 1.28 3.314 533051 1.16 
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CONCLUSION 
A simple, sensitive, rapid and economical stability indicating RP-HPLC 
method was developed and validated for the assay of Tinidazole and Diloxanide 
Furoate in combined tablet formulation. This method yielded high recoveries with 
good linearity and precision. It can be concluded that the proposed method is a good 
approach for obtaining reliable results and found to be suitable for the routine 
analysis of Tinidazole and Diloxanide Furoate combined tablet formulation. 
 From these studies we reported the % of degradation produtcts in various 
conditions like Acid hydrolysis, Alkali hydrolysis, Oxidation, Heat, UV and Neutral 
hydrolysis. 
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